<?xml version="1.0" encoding="UTF-8"?><feed
	xmlns="http://www.w3.org/2005/Atom"
	xmlns:thr="http://purl.org/syndication/thread/1.0"
	xml:lang="en-US"
	>
	<title type="text">Liza Gross | The Verge</title>
	<subtitle type="text">The Verge is about technology and how it makes us feel. Founded in 2011, we offer our audience everything from breaking news to reviews to award-winning features and investigations, on our site, in video, and in podcasts.</subtitle>

	<updated>2019-05-22T12:00:00+00:00</updated>

	<link rel="alternate" type="text/html" href="https://www.theverge.com/author/liza-gross" />
	<id>https://www.theverge.com/authors/liza-gross/rss</id>
	<link rel="self" type="application/atom+xml" href="https://www.theverge.com/authors/liza-gross/rss" />

	<icon>https://platform.theverge.com/wp-content/uploads/sites/2/2025/01/verge-rss-large_80b47e.png?w=150&amp;h=150&amp;crop=1</icon>
		<entry>
			
			<author>
				<name>Liza Gross</name>
			</author>
			
			<title type="html"><![CDATA[Embracing Ecstasy]]></title>
			<link rel="alternate" type="text/html" href="https://www.theverge.com/2019/5/22/18628271/mdma-molly-ecstasy-drug-ptsd-therapy-mental-health" />
			<id>https://www.theverge.com/2019/5/22/18628271/mdma-molly-ecstasy-drug-ptsd-therapy-mental-health</id>
			<updated>2019-05-22T08:00:00-04:00</updated>
			<published>2019-05-22T08:00:00-04:00</published>
			<category scheme="https://www.theverge.com" term="Health" /><category scheme="https://www.theverge.com" term="Science" />
							<summary type="html"><![CDATA[On a chilly spring morning in 2017, Boris Heifets took the podium to talk about MDMA in an Oakland, California, hotel ballroom packed with scientists, therapists, patients, and activists. If he noticed the occasional whiffs of incense and patchouli oil coming from the halls of the Psychedelic Science meeting, he didn&#8217;t let on. After all, [&#8230;]]]></summary>
			
							<content type="html">
											<![CDATA[

						
<figure>

<img alt="" data-caption="" data-portal-copyright="" data-has-syndication-rights="1" src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16282065/VRG_ILLO_3421_001.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" />
	<figcaption>
		</figcaption>
</figure>
<p>On a chilly spring morning in 2017, Boris Heifets took the podium to talk about MDMA in an Oakland, California, hotel ballroom packed with scientists, therapists, patients, and activists. If he noticed the occasional whiffs of incense and patchouli oil coming from the halls of the Psychedelic Science meeting, he didn&rsquo;t let on. After all, anyone studying the therapeutic benefits of the drug that sparked an underground dance revolution 30 years ago knows that ravers, Burners, and old hippies flock to this meeting. It&rsquo;s the world&rsquo;s largest gathering on psychoactive substances.</p>

<p>Ecstasy enthusiasts and university professors alike heard several research teams report that MDMA helped patients recover from post-traumatic stress disorder (PTSD) and other disabling psychiatric conditions after conventional treatments had failed. Meeting rooms buzzed with excited chatter about the prospect of MDMA getting approved as a prescription therapy for PTSD. That could come as early as 2021 if it proves safe and effective in large clinical studies that are just getting underway. For many advocates of this work, regulatory approval can&rsquo;t arrive too soon.</p>

<p>But Heifets, a Stanford neuroanesthesiologist, had come to lay out an even grander role for the drug federal officials banned in 1985 in a futile effort to quash the burgeoning rave scene. Psychiatric treatments lag decades behind the rest of medicine, even though serious mental disorders carry just as much risk of disability and death as cardiovascular disease, Heifets explained. Psychiatrists desperately need more targeted therapies to give their patients the same kind of rapid, enduring relief that stents and bypass surgery provide for heart patients. He thought they&rsquo;d benefit from thinking like surgeons. &ldquo;I don&rsquo;t want to suggest that we can cure psychiatric disease in 30 minutes in the operating room,&rdquo; Heifets said. But we <em>can</em> harness powerful drugs like MDMA that act like a surgeon&rsquo;s knife to alter consciousness and exorcise psychological demons.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>MDMA’s therapeutic power may come from strengthening the bond between therapist and patient</p></blockquote></figure>
<p>For many at the meeting and in the reemerging field of what some call psychedelic medicine, there&rsquo;s no reason to look further than MDMA. A few hours after Heifets spoke, two therapists who used MDMA in sessions with 28 PTSD patients in Colorado reported that 19 participants no longer met the criteria for their diagnoses a year after treatment. MDMA helps melt the walls people hide behind to protect themselves, said Marcela Ot&rsquo;alora, the principal investigator of <a href="https://journals.sagepub.com/doi/full/10.1177/0269881118806297">the study</a>. That allows patients to explore the coping strategies that have failed them for so long. Other teams reported encouraging results from small studies using MDMA to alleviate severe anxiety in adults with autism and in people confronting life-threatening illnesses.</p>

<p>MDMA&rsquo;s therapeutic power may come from strengthening the bond between therapist and patient by enhancing feelings of trust, emotional openness, and empathy, Heifets told the audience, pointing to the commentary he and his mentor, Robert Malenka, <a href="https://www.cell.com/fulltext/S0092-8674(16)30853-4">published in the journal <em>Cell</em></a><em>. </em>To his surprise, a few therapists approached him after the talk to say they quote the paper to tell their patients that the world needs more empathy.</p>

<p>There&rsquo;s no question that MDMA is showing therapeutic promise and could potentially help a range of socially debilitating disorders, Heifets allows. But MDMA, an amphetamine derivative, can raise heart rate and blood pressure, which can prove dangerous for people with cardiac and vascular problems. Though ecstasy is almost never pure MDMA, recreational use can cause panic attacks. In rare cases, it can trigger <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166901/">psychosis in susceptible individuals</a>, which is an unnerving experience ravers have shared on <a href="https://www.reddit.com/r/MDMA/comments/6vrzm5/mild_psychosis_after_mdma/">Reddit</a>. Such risks, combined with its bad rap as a party drug, may limit its ability to help patients, Heifets cautions. He&rsquo;s convinced that MDMA has an even greater potential to revolutionize psychiatric care by giving scientists clues about how to develop next-generation drugs. Ideally, those drugs would be more clearly targeted and have fewer risks than MDMA. Potentially, they could even treat more disorders.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>What they’re saying doesn’t matter, but the deep emotional connection they’re experiencing does</p></blockquote></figure>
<p>If psychiatrists are ever going to catch up with the rest of medicine, they need a better understanding of how the brain works so they can guide it back to health when it breaks down. MDMA is the only psychoactive drug that enhances positive social interactions and empathy. Heifets believes this offers researchers a unique opportunity to probe the brain.</p>

<p>The same properties that make ecstasy-fueled ravers hug between dance grooves also make the drug uniquely suited to help scientists figure out how the brain supports social behaviors. Because its powerful effects don&rsquo;t last long, researchers can model those behaviors in animals and link them to cellular networks in the brain. Go to a rave, and you&rsquo;ll find people glassy-eyed, staring inches from each other&rsquo;s faces in rapt conversation, Heifets says. What they&rsquo;re saying doesn&rsquo;t matter. The deep emotional connection they&rsquo;re experiencing, however, does. &ldquo;That&rsquo;s what we&rsquo;re after. How can we bottle that?&rdquo;</p>

<p>If scientists can capture that magic, he believes, they can sidestep the inherent difficulties of working with a demonized substance steeped in the trappings of a subculture that still inhabits the fringes of society. After the Colorado investigators described how they used MDMA in therapy, a woman in the audience complimented them on the power of their aura, which she said was violet blue and &ldquo;pretty incredible.&rdquo; After a brief pause, Ot&rsquo;alora smiled and thanked the woman, who said she works in the Akashic Records, described by adherents as a sort of cosmic transcript of everything that has ever happened in the history of the world.</p>

<p>Talk of auras and Akashic Records comes with the territory at a meeting with &ldquo;psychedelic&rdquo; in the name, and most researchers take it in stride. They&rsquo;re waiting to see if mainstream medicine will embrace MDMA, assuming the promising results from early PTSD studies hold up under the scrutiny of the larger clinical trials. But Heifets doesn&rsquo;t want to take any chances that shifting political winds will once again shut down work with the still-popular club drug &mdash; along with any hope of ushering in a new era of psychiatry.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16291307/VRG_ILLO_3421_005.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="" />
<p>Heifets works in Malenka&rsquo;s lab in one of the nation&rsquo;s largest regenerative medicine facilities. The center was built a decade ago to foster groundbreaking therapies for some of medicine&rsquo;s most intractable diseases. A massive Chihuly chandelier hangs just inside the center&rsquo;s front entrance where the sculptor&rsquo;s trademark glass tendrils evoke the networks of neurons that hold the secrets to health and disease. It&rsquo;s just a short walk from the lab to the hospital where Heifets spends one day a week tending to brain surgery patients.</p>

<p>Heifets didn&rsquo;t set out to study a controlled substance. &ldquo;My mom told me I should never study psychedelics,&rdquo; he says with an impish grin. &ldquo;It&rsquo;s a good way to kill a promising career.&rdquo;</p>

<p>Still, MDMA piqued his interest even as an undergrad. So when he wandered into Malenka&rsquo;s lab one day and heard him speaking with a colleague about a controlled substance application to do research with MDMA, he went &ldquo;full in.&rdquo;</p>

<p>Heifets was just seven years old in the summer of 1984 when the Drug Enforcement Administration proposed <a href="http://www.maps.org/research-archive/dea-mdma/pdf/0194.PDF">new rules to ban</a> MDMA under Schedule I of the Controlled Substances Act, citing &ldquo;illicit trafficking,&rdquo; high abuse potential and &ldquo;no legitimate medical use.&rdquo; By then, ecstasy had become so popular, Heifets says, that you could buy it with a credit card over the counter at clubs in Texas.</p>

<p>The allure of MDMA&rsquo;s feel-good effects has captured the imagination of adventurers ever since a trailblazing cadre of psychotherapists started using it in the late 1970s. MDMA was discovered in 1912 by German chemists looking for drugs to stop bleeding. It was rediscovered in 1976 by chemist Alexander Shulgin. The legendary psychedelic chemist famously cataloged the effects of <a href="https://www.amazon.com/Pihkal-Chemical-Story-Alexander-Shulgin/dp/0963009605">nearly 200 psychedelic compounds</a> he&rsquo;d made in his home lab. He reported feeling &ldquo;<a href="https://erowid.org/library/books_online/pihkal/pihkal109.shtml">pure euphoria</a>&rdquo; on MDMA, which he called his &ldquo;low-calorie Martini&rdquo; with the &ldquo;special magic,&rdquo; and shared the compound with psychotherapists he thought might find it of use.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“It makes you love everybody. Now, who doesn’t want to take ecstasy?”</p></blockquote></figure>
<p>Those therapists had seen more than a thousand MDMA-assisted breakthroughs with patients, with no major side effects, by the time the government moved to criminalize the drug. Many of them petitioned federal officials to keep it available for their patients. Philip Wolfson, a San Francisco-area psychiatrist who&rsquo;d used MDMA in hundreds of therapy sessions, testified that the drug had helped patients in severe emotional distress with a poor prognosis. &ldquo;I am extremely concerned that this promising new psychotherapeutic agent will be lost to the medical profession,&rdquo; he said.</p>

<p>The government&rsquo;s campaign to ban a drug with potential medical benefits caught the attention of the era&rsquo;s king of daytime talk TV, Phil Donahue. In 1985, he devoted an entire show to MDMA. &ldquo;It makes you love everybody,&rdquo; Donahue said. &ldquo;Now, who doesn&rsquo;t want to take ecstasy?&rdquo; Several people on the show explained how MDMA had helped them come to terms with life-threatening illnesses and heal fractured family relationships in therapy. Chicago addiction expert Charles Schuster, however, said he had &ldquo;great concern&rdquo; about MDMA because he and his colleagues had found that MDA, a chemical cousin, produced long-term brain damage in rats. &ldquo;If MDA does this,&rdquo; Schuster warned, &ldquo;then I have reason to suspect that MDMA may as well.&rdquo;</p>

<p>That was all DEA deputy assistant administrator Gene Haislip, who also condemned MDMA on Donahue&rsquo;s show, needed to hear. A month after appearing on <em>Donahue</em>, Haislip announced an emergency ban on MDMA.</p>

<p>The DEA&rsquo;s ban effectively shut down research on MDMA&rsquo;s medical benefits, but it did nothing to stop the explosion of underground ecstasy-fueled parties where DJs prided themselves on spinning the most eclectic electronica. Filmmakers mined raves&rsquo; trance-inducing beats and light shows as the backdrop for thrillers, crime capers, documentaries, and love stories. Irvine Welsh of <em>Trainspotting</em> fame explored his fascination with &ldquo;rolling&rdquo; on ecstasy in a collection of &ldquo;chemical romance&rdquo; stories, one of which was eventually adapted for the big screen.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16284300/VRG_ILLO_3421_006.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="" />
<p>Meanwhile, Schuster was tapped to head the National Institute of Drug Abuse (NIDA), which showered scientists investigating MDMA&rsquo;s toxicity with millions of federal dollars. It didn&rsquo;t take long for the NIDA&rsquo;s investment to pay off. In 2002, researchers led by George Ricaurte &mdash; a co-author on Schuster&rsquo;s MDA study &mdash; <a href="https://pdfs.semanticscholar.org/a1f0/d7715c44a567db34f65034f6ed9ac5ee8f04.pdf">reported</a> in the prestigious journal <em>Science</em> that recreational doses of ecstasy could cause permanent brain damage in monkeys and possibly lead to Parkinson&rsquo;s disease. Psychiatrists familiar with the drug <a href="https://science.sciencemag.org/content/300/5625/1504/tab-pdf">questioned</a> the plausibility of the $1.3 million study, which was funded partly by grants on methamphetamine toxicity. Politicians, meanwhile, cited the research to push the <a href="https://www.congress.gov/bill/108th-congress/senate-bill/226/text">Illicit Drug Anti-Proliferation Act</a> &mdash; originally introduced in 2002 by Sen. Joe Biden (D-DE) as the <a href="https://www.congress.gov/bill/107th-congress/senate-bill/2633/text?q=%257B%2522search%2522%253A%255B%2522RAVE+act%2522%255D%257D&amp;r=6&amp;s=2">Reducing Americans&rsquo; Vulnerability to Ecstasy (RAVE) Act</a> &mdash; to imprison and fine club owners and promoters for allowing MDMA on their property.</p>

<p>Five months after Congress passed its anti-rave legislation, Ricaurte reported that he&rsquo;d mistakenly given his animals meth, not MDMA, and <a href="https://www.ncbi.nlm.nih.gov/pubmed/12970544">retracted the paper</a>. The fiasco, described as an &ldquo;almost laughable laboratory blunder,&rdquo; got its own chapter in the book <em>When Science Goes Wrong: Twelve Tales from the Dark Side of Discovery.</em> But the damage had been done. Federal officials continued to bankroll their preoccupation with proving that MDMA causes brain damage while ignoring known risks along with its healing potential.</p>

<p>It took researchers almost 20 years after the ban to get federal permission to test MDMA as an experimental therapy. But federal agencies don&rsquo;t fund clinical studies on the drug, forcing researchers to rely on nonprofit sources such as the Multidisciplinary Association for Psychedelic Studies (MAPS).</p>

<p>MAPS director Rick Doblin, who founded the organization in 1986, has been instrumental both in getting the Food and Drug Administration&rsquo;s permission to test MDMA in people and in shepherding it through the drug approval process. Although MDMA could gain FDA approval for PTSD within two years, Doblin is working to make it available as soon as August under the agency&rsquo;s expanded access program. The program gives patients with severe or life-threatening illnesses access to experimental drugs when no other suitable options exist. They&rsquo;ll have to pay for the drug themselves and recognize that there could be risks since the drug hasn&rsquo;t been approved yet, Doblin explains.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>MDMA could get the green light from the FDA as a prescription drug for PTSD within two years</p></blockquote></figure>
<p>To qualify for the trial, patients will need to have PTSD and tried multiple therapies that didn&rsquo;t work. MAPS is training therapists to work with MDMA, and it&rsquo;s setting up expanded access sites around the country, Doblin says.</p>

<p>While Doblin&rsquo;s trying to make up for time lost to restrictive drug laws, Heifets worries about moving too fast. &ldquo;MDMA might work for a lot of people, but there&rsquo;s going to be a large subset for whom it may create problems,&rdquo; he says. The clinical trials exclude people with conditions that MDMA might exacerbate, and they give the drug under closely supervised conditions. Using pure MDMA in this way has revealed minimal risks.</p>

<p>That&rsquo;s not what concerns Heifets. Rather, he&rsquo;s concerned about what might happen if MDMA is given in unrestricted, unsupervised settings. Say therapists use the drug without following the carefully crafted <a href="https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/TreatmentManual_MDMAAssistedPsychotherapyVersion+8.1_22+Aug2017.pdf">MAPS protocol</a>. Who will help people manage the tidal wave of emotions that come up without feeling overwhelmed? Plus, some psychiatric drugs don&rsquo;t mix with MDMA, so patients will have to be weaned off their meds, Heifets says. &ldquo;Who&rsquo;s watching that process? We&rsquo;re in new territory here.&rdquo;</p>

<p>Ideally, everyone who provides MDMA-assisted therapy will have received <a href="https://maps.org/training">MAPS training</a>. But expanding use from a few hundred to the millions of people with PTSD raises the potential for a susceptible person to have a bad reaction that triggers another government backlash, Heifets says. &ldquo;How are we going to avoid that outcome this time?&rdquo;</p>

<p>That&rsquo;s why he wants to focus on nailing down the brain networks associated with MDMA&rsquo;s heightened feelings of emotional closeness and empathy. Learning how MDMA works could point to other treatments, maybe ones with fewer risks.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16284719/VRG_ILLO_3421_004.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="" />
<p>Heifets knew he wanted to study the brain from an early age. But at medical school, he grew increasingly frustrated with his profession&rsquo;s failure to help people. During a rotation at the Bronx Psychiatric Center, where most patients had failed to respond to every treatment offered, it hit him just how little doctors knew about the roots of psychological distress. &ldquo;I was so dissatisfied with our ability to do anything,&rdquo; he says.</p>

<p>A stint in the operating room gave him hope that he could find a way to help people. Psychiatrists are stuck with &ldquo;wimpy,&rdquo; often ineffective drugs that take weeks or months to kick in, he says. But anesthesiologists have access to the most powerful psychoactive drugs in the hospital and can monitor major changes in consciousness in ways that aren&rsquo;t possible outside the OR. That&rsquo;s when he started thinking: what if psychiatrists could harness potent consciousness-altering drugs to heal broken brains the way cardiologists use surgery to repair broken hearts?</p>

<p>&ldquo;This is really where psychiatry meets anesthesia,&rdquo; he says. Anesthesiologists rely on potent drugs that quickly alter consciousness so surgical patients don&rsquo;t feel physical pain. Similarly, psychiatrists working with drugs like MDMA can harness fast-acting mind-bending drugs to mold the brain&rsquo;s perception of psychological distress. Researchers reported 20 years ago that MDMA, in the proper therapeutic setting, alleviates the fear that prevents patients from revisiting traumatic events, a vital part of the healing process. Exactly how MDMA does that still remains unclear.</p>

<p>A few years ago, the Department of Veterans Affairs declared psychotherapy to be the definitive treatment for PTSD; conventional drugs mostly just mask symptoms. But therapy often fails because people can&rsquo;t bear to relive their trauma. Studies show an <a href="https://www.ptsd.va.gov/publications/rq_docs/V28N4.pdf">increased risk</a> of suicide for veterans with PTSD. Effectively, people are dying for want of better therapies. The success stories from when MDMA was still legal convinced second-generation researchers like Michael Mithoefer that the drug might jump-start the psychological healing process. But whether it could pass muster as a standard treatment had never been pursued in formal research until Mithoefer, a clinical assistant professor of psychiatry at the Medical University of South Carolina, launched the first study with MAPS nearly two decades ago.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>A lot of the safety data, ironically, came from government efforts to demonize the drug</p></blockquote></figure>
<p>Today Mithoefer, a PTSD specialist, is overseeing clinical trials of MDMA-assisted therapy for hundreds of patients at 15 sites in North America and Israel. If all goes well in these formal studies, MDMA could get the green light from the FDA as a prescription drug for PTSD within two years. He&rsquo;s cautiously optimistic. &ldquo;We have to wait to see the results before we can say that we&rsquo;ve definitively established safety and efficacy,&rdquo; Mithoefer says. &ldquo;It&rsquo;s looking promising, but we need to see what happens.&rdquo;</p>

<p>To get FDA approval, Mithoefer and his team don&rsquo;t have to show <em>how </em>MDMA works. (&ldquo;If we did, Prozac would never have been approved,&rdquo; he says.) Still, he says, there may well be other drugs that are even better than MDMA.</p>

<p>As far as MAPS&rsquo;s Doblin is concerned, there&rsquo;s no point in trying to find another MDMA-like drug when the real thing is showing such progress. &ldquo;[Alexander Shulgin] tinkered with the molecule in hundreds of different ways, but ended up feeling that of all the ones that he did actually produce MDMA was still the best at what MDMA does,&rdquo; he says.</p>

<p>Doblin allows that drug companies could potentially improve on MDMA. But they&rsquo;ve shown little interest in a controlled substance with an expired patent that can&rsquo;t deliver a fast return on investment. And nonprofits like MAPS don&rsquo;t have the resources to invest in drug discovery or to produce the amount of safety data the FDA requires.</p>

<p>A lot of that safety data, ironically, came from government efforts to demonize the drug, to no avail. &ldquo;Big governments all over the world have spent hundreds of millions of dollars trying to identify the risks,&rdquo; Doblin says. &ldquo;So we have summarized the world scientific literature on MDMA and presented that to FDA.&rdquo;</p>

<p>Aside from elevated heart rate and blood pressure, the risks include overheating and water intoxication. But it was nothing like the long-term brain damage NIDA seemed so intent on proving. Doblin envisions a day when MDMA will be available far beyond the clinic for everything from couples therapy to personal growth.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16284436/VRG_ILLO_3421_007.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="" />
<p>It&rsquo;s a prospect that concerns some psychiatrists, including Charles Grob who led a recent study using MDMA to ease severe anxiety in autistic adults. The idea of millions and millions of people taking MDMA &ldquo;makes me dizzy,&rdquo; says Grob, director of the Division of Child and Adolescent Psychiatry at&nbsp;Harbor-UCLA Medical Center, Los Angeles. MDMA needs to be administered by trained professionals in special settings with clear-cut safety parameters, he says. Without these measures in place, he worries about &ldquo;the whole enterprise going off the rails.&rdquo;</p>

<p>Marcela Ot&rsquo;alora, who runs the MAPS PTSD study in Colorado, agrees that MDMA may not be for everybody. About three-quarters of PTSD patients in her study learned to cope with their symptoms, but that leaves a quarter who did not. &ldquo;It&rsquo;s great if we can find something else that maybe would help people that are not going to be helped by MDMA,&rdquo; she says.</p>

<p>That&rsquo;s another thing that suggests Heifets&rsquo; approach might be a good one: finding better treatments depends on getting a better handle on how they work, which is insight that&rsquo;s missing for most psychiatric drugs.</p>

<p>Scientists stumbled upon the original antidepressants <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181192/">by accident</a>: patients who took new drugs for tuberculosis in the 1950s reported feelings of euphoria. That led to theories about tinkering with neurotransmitters to improve moods and decades of drug development. That pipeline, however, is now dry, Heifets says.</p>

<p>Both Prozac &mdash; a selective serotonin reuptake inhibitor (SSRI) &mdash;&nbsp;and MDMA affect the same brain chemical: serotonin, which regulates mood, learning, and memory. But no one gets an insatiable urge to approach strangers after taking Prozac, Heifets points out. Clearly, they act in different ways.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“I’m the only one in the lab working on MDMA.”</p></blockquote></figure>
<p>Psychiatrists have long treated the brain as a chemical soup and enlisted drugs to target one chemical after another, he says. But those drugs can cause terrible side effects because they&rsquo;re not specific enough. Increasingly, researchers view psychiatric disorders as changes in the connections between specific groups of cells, or circuits, in the brain. Different regions of the brain talk to each other to support normal responses to everyday events, like meeting strangers or navigating potential threats. When those lines of communication between circuits break down, normal responses do, too. Figuring out how MDMA changes these connections to enhance emotional closeness may help explain what goes wrong in people who can&rsquo;t manage social situations, Heifets says.</p>

<p>In general, psychiatry hasn&rsquo;t paid much attention to how social factors affect mental health, says Harriet de Wit, director of the University of Chicago&rsquo;s Human Behavioral Pharmacology Laboratory. Yet depression, schizophrenia, and psychosis, for example, share a strong sense of withdrawal from social interactions and society, even though the underlying process likely differs, she says. A better understanding of how MDMA works might point to other drugs that can specifically affect the different social processes.</p>

<p>Heifets has been trying to do just that under the guidance of Malenka, a leader in enlisting cutting-edge tools in rodents to understand how changes in brain circuits affect behavior. &ldquo;Rob&rsquo;s been my biggest advocate and mentor,&rdquo; Heifets says. &ldquo;I&rsquo;m the only one in the lab working on MDMA.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“MDMA really taps into something that enhances the ability to have the most positive social experience.”</p></blockquote></figure>
<p>&ldquo;This is where Boris and I bonded,&rdquo; Malenka says. &ldquo;It&rsquo;s just a fascinating drug that I&rsquo;ve been wanting to study for, my god, probably over 30 years because I think it&rsquo;s a window into the brain and how the brain works.&rdquo;</p>

<p>Malenka believes MDMA could ultimately help people whose illness makes healthy social interactions difficult or impossible. &ldquo;Imagine going through life where you can&rsquo;t have a positive social experience,&rdquo; he says. &ldquo;MDMA really taps into something that enhances the ability to have the most positive social experience.&rdquo; But where Doblin sees a role for MDMA for everything from PTSD to personal growth, Malenka sees a powerful compound with the potential to harm as well as heal. That&rsquo;s not demonizing the drug, he says, but recognizing the need to understand the good <em>and </em>the bad. For Malenka, MDMA is like any other substance that can affect brain function. Drilling into the details of how it works will help clinicians make rational decisions about how to use it, he says.</p>

<p>Toward that end, Malenka hopes the experiments they&rsquo;re doing in mice will influence the clinical studies by showing, for example, that a specific brain circuit isn&rsquo;t functioning properly in a specific psychiatric disorder. That, in turn, could suggest new therapies that drug companies would be willing to invest in.</p>

<p>Recent <a href="https://web.stanford.edu/group/dlab/media/papers/walshNature2018.pdf">work from Malenka&rsquo;s lab</a> shows that the release of serotonin in a region of the brain&rsquo;s &ldquo;reward circuit&rdquo; &mdash; which reacts to pleasurable activities like eating and sex &mdash; can enhance social behavior in mice bred to have autism-like behaviors. Research from other groups working in mice showed that MDMA increases &ldquo;fear extinction,&rdquo; a decline in fear responses triggered by trauma, which appears to be critical for successful PTSD therapy.</p>

<p>MDMA may be acting like a sort of psychological accelerant, hastening changes in the brain that lay the groundwork for recovery.&nbsp;The idea of starting a process as a bridge to healing is a concept that&rsquo;s been missing in psychiatry, Heifets says. The trick is figuring out novel or existing drugs that can build that bridge. &ldquo;We probably have a ton of drugs that are already FDA approved that we just don&rsquo;t know what their potential is,&rdquo; he says.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/16284129/VRG_ILLO_3421_003.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="" />
<p>Beyond exploring how MDMA works in the brain, psychologists are still figuring out how it works in the therapist&rsquo;s office. &ldquo;We&rsquo;re still kind of waving our hands around,&rdquo; says de Wit. &ldquo;There&rsquo;s general agreement that it&rsquo;s not just the drug itself, but it&rsquo;s the combination of how the drug changes the therapeutic interaction. I don&rsquo;t think we know enough about what happens in therapeutic interactions to know whether it&rsquo;s something about the connection that the patient feels with the therapist or their willingness to be open about their emotions or whether they feel less judged.&rdquo;</p>

<p>Whatever is going on is a radical departure from standard psychiatric treatments. Rather than taking SSRIs indefinitely to keep symptoms from returning &mdash; assuming they ever go away &mdash; patients take just a few doses of MDMA in therapy and experience lasting relief.</p>

<p>At the Oakland Psychedelic Science meeting, where Heifets spoke two years ago, several practitioners emphasized the power of the relationship between therapist and patient to aid recovery. Psychiatrist Philip Wolfson, who urged the DEA to keep MDMA legal in the 1980s, said that MDMA revolutionized psychotherapy in part because therapists had to stay with people for as long as they needed. &ldquo;That meant we exposed ourselves more as therapists,&rdquo; he said. &ldquo;And we changed from the 50-minute hour, which was always repugnant to me.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“Now we have data saying that, yes, this is actually helping. It’s no longer anecdotal.”</p></blockquote></figure>
<p>Wolfson reported preliminary results from sessions using MDMA in 18 patients facing life-threatening illnesses. His study, like other MAPS-funded studies, involved intensive psychotherapy lasting at least eight hours in three sessions. The initial analysis for a subset of patients showed marked improvement in scores for both depression and fear of dying for those who took MDMA. But patients who took placebos <em>also</em> improved, a result Wolfson attributed to the effects of such intensive psychotherapy. Even so, after he recently finished the full analysis, it was clear that the MDMA group had the bigger drop in anxiety compared to the placebo group. Everyone had the option to do a follow-up MDMA session, he told me. Everyone opted for MDMA, and everyone felt even better as a result.</p>

<p>Ot&rsquo;alora, the PTSD researcher who handled the compliment on her aura without missing a beat, has seen similar therapeutic breakthroughs without MDMA. But it can take years. With MDMA sessions, people often show improvement right away, she says, as the drug gives them the inner resources to work through their trauma. Even people who still had trouble coping with their PTSD symptoms after the treatment said it helped them when nothing else had, she says. &ldquo;Every single participant I&rsquo;ve worked with has said, &lsquo;I don&rsquo;t understand why this is not available to everybody who&rsquo;s suffering.&rsquo;&rdquo;</p>

<p>Researchers feel buoyed by the promising results. Yet they&rsquo;re keenly aware of the stigma around drugs like MDMA. &ldquo;Now we have data saying that, yes, this is actually helping. It&rsquo;s no longer anecdotal,&rdquo; says Ot&rsquo;alora. &ldquo;And there are still people who are incredibly skeptical.&rdquo;</p>

<p>Blame George Ricaurte&rsquo;s fateful lab blunder. It doesn&rsquo;t matter that his paper was retracted. It&rsquo;s still on the internet, including the <a href="https://archives.drugabuse.gov/sites/default/files/directors_report_2-03.pdf">NIDA&rsquo;s website</a>. Even today, Ot&rsquo;alora says, people tell her they read that MDMA causes holes in your brain. And she&rsquo;s seen both patients and parents of younger patients bristle at the idea of using what they see as a club drug for therapy &mdash; until they see the results.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>now, scientists who study MDMA don’t have to worry about throwing away their careers</p></blockquote></figure>
<p>For years, meetings like Psychedelic Science were the only place scientists researching psychoactive drugs were invited to speak. &ldquo;The government and industry have not put one cent into this research, so it has to be supported by donors,&rdquo; Mithoefer says.</p>

<p>Still, attitudes among psychiatrists have changed radically since the first MDMA studies, Mithoefer says. Now, he and his colleagues are presenting their work mostly at mainstream meetings where he&rsquo;s seeing a lot of excitement around the idea that drugs like MDMA can trigger a therapeutic process with higher rates of success. &ldquo;And nobody&rsquo;s bringing up their auras,&rdquo; he says with a laugh.</p>

<p>And now, scientists who study MDMA don&rsquo;t have to worry about throwing away their careers.</p>

<p>For Heifets, one of the most intriguing things to come from lab work on MDMA is the notion that a drug can strengthen the bond between patient and therapist. &ldquo;There&rsquo;s no real precedent for that in psychiatry,&rdquo; he says. And that may be where the path to transforming psychiatry begins: in abandoning the notion that you can treat complex human brain disorders with drugs alone. It&rsquo;s time to recognize that you can&rsquo;t treat millions of veterans with PTSD by giving them a pill, whatever it is, and sending them home, Heifets says. The research on MDMA is showing that you might be able to kick off recovery with a drug, but interaction with other people matters, too. In fact, the relationships with other people &mdash; like therapists &mdash;&nbsp;may matter even <em>more.</em></p>

<p class="has-end-mark">&ldquo;Fundamentally, there is a need for some kind of human connection,&rdquo; he says. &ldquo;We can&rsquo;t just farm out all of our psychiatric issues to the drug industry.&rdquo;</p>
						]]>
									</content>
			
					</entry>
			<entry>
			
			<author>
				<name>Liza Gross</name>
			</author>
			
			<title type="html"><![CDATA[Smoke Screen]]></title>
			<link rel="alternate" type="text/html" href="https://www.theverge.com/2017/11/16/16658358/vape-lobby-vaping-health-risks-nicotine-big-tobacco-marketing" />
			<id>https://www.theverge.com/2017/11/16/16658358/vape-lobby-vaping-health-risks-nicotine-big-tobacco-marketing</id>
			<updated>2017-11-16T09:00:22-05:00</updated>
			<published>2017-11-16T09:00:22-05:00</published>
			<category scheme="https://www.theverge.com" term="Features" /><category scheme="https://www.theverge.com" term="Health" /><category scheme="https://www.theverge.com" term="Science" />
							<summary type="html"><![CDATA[Samir Soneji had no idea what he was getting into when he agreed to talk about the potential risks of vaping at the first US E-Cigarette Summit in Washington, DC this past May. His first clue was the booing. As a professor at the Dartmouth Institute for Health Policy and Clinical Practice, Soneji studies how [&#8230;]]]></summary>
			
							<content type="html">
											<![CDATA[

						
<figure>

<img alt="" data-caption="" data-portal-copyright="" data-has-syndication-rights="1" src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/9689095/acastro_171013_2138_0001.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" />
	<figcaption>
		</figcaption>
</figure>
<p>Samir Soneji had no idea what he was getting into when he agreed to talk about the potential risks of vaping at the first US E-Cigarette Summit in Washington, DC this past May. His first clue was the booing.</p>

<p>As a professor at the Dartmouth Institute for Health Policy and Clinical Practice, Soneji studies how gaps in tobacco regulation affect health. Two years before the conference, he&rsquo;d reported in&nbsp;<a href="http://jamanetwork.com/journals/jamapediatrics/fullarticle/2020785"><em>JAMA Pediatrics</em></a> that young people who smoke hookah or use &ldquo;snus,&rdquo; a form of moist smokeless tobacco, are twice as likely to try cigarettes as kids who don&rsquo;t. He suspected that e-cigarettes, with kid-friendly flavors like &ldquo;Cinnamon Roll&rdquo; and &ldquo;Peanut Butter Cup,&rdquo; carried a similar risk. And that&rsquo;s exactly what he and several colleagues discovered in a <a href="http://jamanetwork.com/journals/jamapediatrics/fullarticle/2634377">recent review</a> of studies that tested that possibility.</p>

<p>Evidence that tobacco companies targeted teens and nonsmokers with <a href="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm532563.htm">candy- and fruit-flavored cigarettes</a> prompted the Food and Drug Administration to ban them in 2009 under the Family Smoking Prevention and Tobacco Control Act. But those restrictions do not apply to e-cigarettes and hookahs, even though the FDA <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm506676.htm">extended its authority</a> in August 2016 to include all forms of tobacco. &nbsp;</p>
<div class="wp-block-vox-media-highlight vox-media-highlight alignnone"><h3 class="wp-block-heading" id="ILqH3K">Key points</h3>

<ul class="wp-block-list"><li>The e-cigarette market is expected to be worth $34 billion by 2021, and is increasingly dominated by tobacco companies such as Reynolds American and Altria (formerly known as Philip Morris).</li><li>Studies into the argument that vaping leads to smoking cessation continue to have mixed findings. Meanwhile, studies on the health risks of vaping have different results based on whether they were funded by tobacco companies, or non-affiliated public researchers.</li><li>Big Tobacco has been developing e-cigarette devices since the early 1960s, but eventually avoided marketing them because, according to executives, smokeless tobacco “complicates our efforts to resist the FDA’s attempts to regulate the tobacco industry.”</li><li>Major tobacco companies co-opted and heavily invested in the promotion of the concept of “harm reduction,” as opposed to smoking cessation, as a means of gaining access to public health experts and casting themselves as socially responsible corporations. It is the same argument vaping promoters use today.</li><li>E-cigarette manufacturer NJOY and importer Smoking Everywhere have hired the same firms that previously helped the tobacco industry evade regulation and defeat smokers’ liability claims for years. Their allies have hired law firms that have successfully defended major tobacco companies from class action lawsuits.</li><li>Philip Morris, Reynolds American, and its allies paid lobbyists nearly $1.2 million to fight a California bill to prohibit the sale of e-cigarettes in vending machines and regulate them like any other tobacco product.</li><li>Tobacco and vaping industries spent nearly $10 million to fight regulations on e-cigarettes and related legislation in California since 2009.</li></ul></div>
<p>Soneji figured that people who came to a conference about the science and regulation of e-cigarettes actually wanted to hear the latest science, whatever the data showed. So he told the audience what he and others had found: youth who vaped were more likely to start smoking cigarettes than those who didn&rsquo;t. What&rsquo;s more, kids who made the leap from e-cigs to cigarettes probably wouldn&rsquo;t otherwise have started smoking, he explained, because they didn&rsquo;t suffer from anxiety or depression or use alcohol or drugs &mdash; risk factors associated with youth smoking. He also shared evidence that &ldquo;fun&rdquo; candy-flavored e-cigarettes attract kids, just as flavored cigarettes did, and that, because labels often misrepresent <a href="https://academic.oup.com/jat/article/40/6/403/2237800/Concentration-of-Nicotine-and-Glycols-in-27">nicotine levels in the devices</a>, even kids who think they&rsquo;re vaping only flavors could be inhaling nicotine.</p>

<p>The booing was not the only sign to Soneji that this was not a typical scientific conference. He later joined a Q&amp;A panel before the morning break. There, a Johns Hopkins researcher who said he consults for pharmaceutical companies and Reynolds American &mdash; which makes VUSE, the top-selling e-cig brand in the US &mdash; asked the panel when public health officials were going to communicate positive messages about how vaping reduces harm, like they do about using clean needles and condoms to stem the spread of disease. Soneji said it would be premature and dangerous to recommend e-cigarettes to help smokers quit, given the lack of rigorous scientific evidence to support it. Minutes later, the head of an anti-smoking organization rose from the audience to dismiss his call for more evidence as &ldquo;rubbish.&rdquo; The crowd laughed and cheered.</p>

<p>Many people in the audience, Soneji would discover, had an emotional or financial interest in vaping &mdash; and they didn&rsquo;t pay up to $1,100 a ticket to hear anyone question the benefits of e-cigarettes. &ldquo;I didn&rsquo;t realize just how many people would be from the industry, and whose job and livelihood is [tied] to e-cigarettes,&rdquo; he says. &ldquo;Hearing about the harms of vaping came across as threatening to their existence.&rdquo;</p>

<p>Many people Soneji spoke to after his talk argued that e-cigarettes save lives. They told him it&rsquo;s the tar in cigarette smoke that causes lung cancer, and since e-cigarettes don&rsquo;t have tar, there&rsquo;s nothing to worry about. An ex-smoker-turned-vaper who had opened a vape shop to help others quit smoking told Soneji that his products were safer because they don&rsquo;t produce cancer-causing tar. While that&rsquo;s true, Soneji says, &ldquo;he was very dismissive of any cardiovascular effects around vaping and nicotine, and around the chemical by-products of heating the e-juice.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“Hearing about the harms of vaping came across as threatening to their existence.” </p></blockquote></figure>
<p>Public health campaigns have so successfully tied smoking to lung cancer that people often don&rsquo;t realize more smokers die of cardiovascular and metabolic diseases than of lung cancer. Soneji tried to tell the shop owner, and many others at the summit, that smoking significantly increases the risk of cardiovascular disease and that <a href="http://jamanetwork.com/journals/jamacardiology/article-abstract/2600166">recent studies</a> suggest e-cigarettes also increase heart attack risk. But they didn&rsquo;t listen to him. They didn&rsquo;t understand how anyone could question the value of a product they believe helps people quit one of the world&rsquo;s deadliest habits.</p>

<p>Online forums are filled with stories from ex-smokers who saw striking health improvements after switching to vaping. &ldquo;I no longer wake up coughing and hacking up gunk for the first two hours of my day. I&#8217;m no longer getting winded doing the smallest things,&rdquo; reported a member of the E-Cigarette Forum, which calls itself &ldquo;the voice of vaping since 2007.&rdquo;</p>

<p>Ex-smokers offer similar testimonials on vaping forums, blogs, and social media groups. The vaping advocacy group Consumer Advocates for Smoke-free Alternatives Association, or CASAA, sells <a href="https://casaa.org/product/vaping-saves-lives-t-shirt/">a T-shirt</a> to drive home the point: &ldquo;Vaping saves lives.&rdquo; &nbsp;&nbsp;&nbsp;&nbsp;</p>

<p>After the e-cigarette summit, a media outlet called Vaping360 <a href="http://vaping360.com/ecig-summit-washington/">described Soneji</a> as &ldquo;the speaker with the most tedious and pedestrian boilerplate anti-vaping agenda,&rdquo; and attacked him and his co-authors as &ldquo;a who&rsquo;s who of <a href="http://vaping360.com/vaping-gateway-smoking/">terrible vaping researchers</a>.&rdquo;</p>

<p>The attacks on Soneji are similar to those lobbed at any individual who speaks out about the possible harms of vaping. On the Facebook page for the 2016 pro-vaping movie <em>A Billion Lives</em>, a woman who described herself as a tobacco treatment specialist dared to say, &ldquo;We don&rsquo;t know yet the exact repercussions of vaping because it hasn&rsquo;t been around long enough. But we do know it causes [scarring] in the lungs.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>The attacks on Soneji are similar to those lobbed at any individual who speaks out about the possible harms of vaping</p></blockquote></figure>
<p>Within minutes, a man who&rsquo;d just posted about how vaping helped him quit smoking told her: &ldquo;STFU you are an idiot and a moron. Clearly you don&rsquo;t know wtf to say cause you would rather people smoke.&rdquo; The next comment is too profanely misogynistic to print.</p>

<p>It&rsquo;s hard to overestimate the power of personal experience. But personal anecdotes, no matter how plentiful or powerful, are no substitute for scientific evidence derived from rigorously designed studies that test alternate hypotheses and control for confounding factors. Scientists are just beginning to test the effects of vaping on the human lung. A <a href="http://ajplung.physiology.org/content/313/2/L193.long">recent review</a> of studies concluded that e-cigarette use may cause &ldquo;significant&rdquo; toxicity to the lung, but noted that more research is needed. Long-term studies clearing e-cigarettes as reasonably safe alternatives to cigarettes have not been done. But that hasn&rsquo;t stopped some vaping advocates from claiming they have.</p>

<p>And they can easily find compromised or less-than-complete studies to support their case. In April,&nbsp;<a href="https://eurekalert.org/pub_releases/2017-04/raba-aet041117.php">British American Tobacco, or BAT &mdash; a major player in the vaping market and the largest tobacco company in the world &mdash; reported</a> that vapor from its Vype e-pen barely affects disease-related genes in a simulated human airway. In a&nbsp;<a href="http://pubs.acs.org/doi/full/10.1021/acs.chemrestox.6b00188?src=recsys&amp;">previous study</a>, <a href="http://pubs.acs.org/doi/full/10.1021/acs.chemrestox.6b00188?src=recsys&amp;">BAT asserted</a> that the device produces 95 percent fewer toxic chemicals than a conventional cigarette. In 2015, a report from Public Health England, an executive agency of the UK&rsquo;s Department of Health, deemed e-cigarettes 95 percent less harmful than cigarettes. But the conclusion was <a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00042-2/fulltext?rss=yes">based partly on research funded</a> by organizations and scientists with ties to tobacco and e-cigarette companies. Two years earlier, a study funded by CASAA reported that e-cigarettes pose minimal risk to users and bystanders.</p>

<p>Publicly funded published studies from researchers with no ties to tobacco or vaping interests, by contrast, have shown that <a href="http://www.sciencedirect.com/science/article/pii/S1438463913001533">chemicals</a> in e-cigarette vapor <a href="http://dx.doi.org/10.1152/ajplung.00170.2016">suppress genes</a> involved in immune defense in human nasal epithelial cells, include&nbsp;<a href="http://pubs.acs.org/doi/full/10.1021/acs.est.6b01741">known respiratory irritants and carcinogens</a>, <a href="http://ajplung.physiology.org/content/313/1/L52.long#sec-26">impair the function of epithelial cells that protect the lungs</a>, and contain <a href="http://www.sciencedirect.com/science/article/pii/S1438463913001533">ultrafine particles and nicotine</a> that could harm vapers and bystanders.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Studies across diverse subjects show that industry-funded research tends to favor the study’s sponsor</p></blockquote></figure>
<p>Why such different conclusions? No one has yet systematically compared the results of vaping studies funded by vested interests to those funded by independent sources, but studies across diverse subjects show that industry-funded research tends to favor the study&rsquo;s sponsor. And we know, thanks to once-secret documents released through leaks and litigation, that tobacco companies <a href="http://tobaccocontrol.bmj.com/content/10/3/218">spent billions of dollars</a> to undermine evidence that cigarettes harm smokers and bystanders. In the <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=qsly0042">infamous Whitecoat Project</a>, Philip Morris hired <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=hxym0071">law firms</a> to find scientists, <a href="http://jech.bmj.com/content/55/8/588.long">aka &ldquo;whitecoats,&rdquo;</a> who would help &ldquo;resist and roll back smoking restrictions,&rdquo; a plan detailed in a formerly <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=khww0048">confidential 1988 memo</a>, and <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=khww0048">keep the controversy about the hazards of secondhand smoke alive.</a></p>

<p>Just a decade ago, the vaping industry &mdash; which includes devices that typically heat nicotine-containing liquids to produce inhalable vapors &mdash; was largely the province of small businesses. Today, the market, which is valued at over $10 billion and expected to be <a href="http://blog.euromonitor.com/2017/06/latest-research-tobacco-2017-edition-data.html">worth $34 billion by 2021</a>, is <a href="https://globenewswire.com/news-release/2017/01/18/906615/0/en/Global-E-cigarette-Vaporizer-Device-and-Aftermarket-Analysis-and-Forecast-2016-2025-Big-Tobacco-Companies-Taken-Over-the-47-Billion-Industry-Through-a-Series-of-Mergers-and-Acquisi.html">increasingly dominated by tobacco</a> companies such as Reynolds American and Altria (formerly known as Philip Morris).</p>

<p>Many <a href="http://www.aemsa.org/featured-link/sfata/">vaping advocates </a><a href="http://thehill.com/blogs/pundits-blog/healthcare/329829-the-rise-of-vaping-has-nothing-to-do-with-big-tobacco">say they&rsquo;re competing with Big Tobacco</a>, which they fear will <a href="http://dailycaller.com/2014/08/08/dont-let-big-tobacco-choke-the-e-cigarette-industry/">stifle innovation</a>. They say that <a href="https://www.atr.org/electronic-cigarettes-should-not-be-taxed-tobacco-products">taxes on e-cigarettes</a> will penalize smokers trying to quit and that regulations requiring companies to disclose the ingredients in e-juice and conform to quality standards will bankrupt small entrepreneurs. Some may well be trying to put the tobacco industry out of business. But others have joined forces with some of the same actors and have deployed the same tactics <a href="http://toxicology.usu.edu/endnote/Bero-AnnRevPubHealth24-100901.pdf">the tobacco industry used to stoke doubts</a> about smoking&rsquo;s dangers while marketing &ldquo;safer&rdquo; delivery systems. They&rsquo;re enlisting veteran tobacco industry law firms to contest federal oversight in court and partnering with tobacco-funded libertarian groups to fight regulation in states and cities, and they&rsquo;re rallying armies of ex-smokers who believe vaping saved their lives.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/9689113/acastro_171013_2138_0002.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="Illustration by Alex Castro / The Verge" /><h1 class="wp-block-heading" id="pWsk9Y">Turning Public Health Experts into the Enemy</h1>
<p>For decades, tobacco control experts worked together to counter marketing campaigns that made smoking sexy. Hard-hitting TV spots featuring smokers disfigured by cancer and speaking through voice boxes, or hooked up to oxygen tanks and gasping for air helped drive a decline in smoking that had begun <a href="https://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/index.htm">in the 1960s</a>. But health alliances forged to stop smoking began to crumble in the mid-2000s with the advent of campaigns to promote &ldquo;reduced harm&rdquo; products like smokeless tobacco and e-cigarettes. While some of these products &mdash; including nicotine patches, lozenges, and gums &mdash; have received FDA approval to treat nicotine addiction after clinical trials showed they were safe and effective, others, including smokeless tobacco and e-cigarettes, have not.</p>

<p>E-cigarettes are theoretically safer than cigarettes because they don&rsquo;t burn tobacco, which produces a noxious mixture of toxic and cancer-causing substances, such as polycyclic aromatic hydrocarbons, aldehydes, and heavy metals like cadmium and arsenic. Instead, the battery-powered devices produce an aerosol mist by heating &ldquo;e-juice,&rdquo; which typically contains flavors and nicotine dissolved in solvents (propylene glycol or vegetable or both) that minimize evaporation until the cocktail is inhaled. Proponents of harm reduction, who advocate offering reduced-risk products to those who can&rsquo;t stop smoking, argue that giving e-cigarettes to smokers is like providing clean needles to IV drug users: individuals can satisfy their craving while reducing their overall disease burden.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Proponents of harm reduction argue that giving e-cigarettes to smokers is like providing clean needles to IV drug users</p></blockquote></figure>
<p>But for a harm-reduction argument to be valid, policy makers need strong evidence that vaping improves smokers&rsquo; health without creating a new set of risks &mdash; to both users and nonusers. So far, the evidence for quitting is mixed, while long-term safety remains unknown. A systematic review of studies of e-cigarettes and smoking cessation <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010216.pub3/full">published last year</a> reported that two clinical trials offer evidence that vaping leads to quitting, but cautioned that they were too small to have confidence in the results. Meanwhile, another <a href="http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00521-4/abstract">review published last year</a>, which included a broader range of studies, concluded that people who used e-cigarettes were actually less likely to quit smoking.</p>

<p>Assessing risks to vapers and bystanders associated with chemicals in e-cigarette vapor has proven difficult because manufacturers keep changing the devices, which now come in over 460 brands and <a href="http://tobaccocontrol.bmj.com/content/23/suppl_3/iii3">close to 8,000</a> different flavors.</p>

<p>Some vaping advocates insist that e-cigarettes emit only harmless water vapor &mdash; echoing <a href="https://web.archive.org/web/20130403100952/http://www.usacig.com/faq.aspx">marketing claims</a> &mdash; and propylene glycol, the same ingredient used in fog machines. The FDA has deemed e-cigarette flavorings and the solvents propylene glycol and glycerin &ldquo;generally recognized as safe&rdquo; for use in food, but that has little bearing on whether they&rsquo;re safe to inhale. Several studies have detected a range of toxic chemicals in e-cigarette vapor, including <a href="https://ehp.niehs.nih.gov/15-10185/">diacetyl</a>, which is associated with the severe respiratory disease known as &ldquo;popcorn lung&rdquo;; <a href="https://www.researchgate.net/profile/Andrey_Khlystov/publication/310823078_Flavoring_Compounds_Dominate_Toxic_Aldehyde_Production_during_E-Cigarette_Vaping/links/583f1a4f08ae8e63e6182588.pdf">aldehydes</a>, which are probable carcinogens; <a href="https://www.ncbi.nlm.nih.gov/pubmed/23467656/">acrolein</a>, a potent irritant often found in air pollution; and the cancer-causing tobacco-specific nitrosamines that are also found in cigarette smoke. The <a href="https://www.ncbi.nlm.nih.gov/pubmed/24575993">few studies</a> of people working with theatrical fog machines found that those working closest to the machines had reduced lung capacity &mdash; and they weren&rsquo;t repeatedly sucking propylene glycol into their lungs like vapers do. What&rsquo;s more, several studies report that heating propylene glycol and glycerin <a href="https://www.nature.com/articles/srep42549.pdf">under normal vaping conditions</a> can produce an array of toxic chemicals, including <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173055">benzene</a>, a known human carcinogen, and fine particles, which can cause heart disease. &nbsp;</p>

<p>Levels of toxic chemicals found in e-cigarette vapor are typically far lower than those found in tobacco smoke, but no one knows the long-term effects of inhaling them.</p>

<p>To figure out whether e-cigarettes reduce harm to smokers, the devices would have to undergo rigorous testing in several clinical trials, just as other nicotine-replacement therapies have. That hasn&rsquo;t happened. When the Public Health England panel concluded that e-cigarettes are 95 percent safer than cigarettes, it relied on assumptions about risks, not on data derived from carefully controlled studies.</p>

<p>&ldquo;Theoretical benefits are not evidence,&rdquo; says Jonathan Klein, scientific director for the American Academy of Pediatrics Julius B. Richmond Center of Excellence, which studies tobacco. To get evidence on relative risks, at a minimum you&rsquo;d need to track the disease rates of separate groups of people using different products to see if vaping reduces disease outcomes, Klein says. And if you want to protect public health, you&rsquo;d prevent nonsmokers and young people from getting addicted, he says. &ldquo;But that&rsquo;s not the way it&rsquo;s been approached.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“Theoretical benefits are not evidence.”</p></blockquote></figure>
<p>Soneji says you could classify e-cigarettes as a net population benefit if the devices were better than cold turkey at helping adult smokers quit, and they didn&rsquo;t attract children. Then they&rsquo;d resemble conventional nicotine-replacement therapy, otherwise known as NRT (think Nicorette gum or Chantix pills). &ldquo;No kids are really interested in NRT,&rdquo; Soneji says. &ldquo;And NRT is better than cold turkey for smokers interested in quitting.&rdquo;</p>

<p>And though e-cigarette lobbyists compare vaping to needle exchange or methadone treatment, there&rsquo;s a critical difference, Soneji says: unlike e-cigarettes, methadone isn&rsquo;t designed to attract people who aren&rsquo;t already addicted. &ldquo;It&rsquo;s not like you can buy mint-flavored methadone.&rdquo;</p>

<p>E-cigarettes, by contrast, are mass-marketed in flavors that appeal to kids, who can buy them online by clicking a link that says they&rsquo;re 18 or older. In 2011, at least four years after e-cigarettes hit the US market, just over 3 percent of 6th through 12th graders had tried e-cigarettes. By 2013, over 8 percent had tried vaping. More than a quarter-million kids who&rsquo;d never smoked cigarettes had tried vaping that year, researchers reported in <a href="https://e-cigarettes.surgeongeneral.gov/documents/2016_sgr_full_report_non-508.pdf"><em>Nicotine and Tobacco Research</em></a><em>; </em>they were nearly twice as likely to start smoking conventional cigarettes as kids who didn&rsquo;t vape. By 2015, e-cigarette use among teens had skyrocketed to 27 percent, surpassing the use of every other tobacco product. In 2017, e-cigarette use among teens dropped for the first time, according to the <a href="https://www.cdc.gov/media/releases/2017/p0615-youth-tobacco.html">latest survey</a> by the Centers for Disease Control and Prevention, though e-cigarettes are still the most favored tobacco product.</p>

<p>Alarmed by the uptake among kids, former surgeon general Vivek Murthy called the devices a &ldquo;<a href="https://e-cigarettes.surgeongeneral.gov/documents/2016_sgr_full_report_non-508.pdf">major public health concern&rdquo;</a> in a report on e-cigarettes last year, which the vaping industry and its allies roundly condemned. William Godshall, a longtime anti-smoking activist who promotes vaping as harm reduction, accused Murthy of lying about vapor research and threatening the lives of vapers and smokers on <a href="https://ejuicemonkeys.com/news/godshall-chronicles-122216/">eJuiceMonkeys.com</a>, which posts his newsletter. The site also posted similar reprisals from the vaping industry and its allies.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>former surgeon general Vivek Murthy called e-cigarettes a “major public health concern”</p></blockquote></figure>
<p>Pro-vaping blogs and online forums regularly praise studies that serve their aims and condemn those that don&rsquo;t. And that&rsquo;s where many of the roughly 8 million vapers and owners of the rapidly rising number of vape shops and lounges &mdash; at <a href="https://www.cdc.gov/pcd/issues/2016/16_0071.htm">8,500 last year</a> and counting, according to the CDC journal <em>Preventing Chronic Disease </em>&mdash; get their information. They&rsquo;re also exchanging information at the growing number of meet-ups and conventions where enthusiasts can mingle with like-minded souls, geek out over the latest gear, and watch &ldquo;cloud chasers&rdquo; compete to blow the most impressive vapor plumes. At conventions like VapeCon, they can stock up on free samples or take a selfie with a seductively dressed Miss VapeCon. For many, vaping isn&rsquo;t just a habit, it&rsquo;s a way of life.</p>

<p>So when <em>The Simpsons</em> mocked industry claims that they didn&rsquo;t market to kids a few years ago, many vapers weren&rsquo;t amused. In the episode, Bart goes to the Kwik-E-Mart to buy e-cigs, and Apu tells him that while they&rsquo;re legal for children in their state, &ldquo;this is not kid stuff.&rdquo; Then Apu asks, &ldquo;Now would you like bubble gum flavor, strawberry shortcake, or watermelon dream?&rdquo; A writer for Vaping360 complained that the show played to &ldquo;common fears and misconceptions.&rdquo;</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/9689137/acastro_171013_2138_0004.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="Illustration by Alex Castro / The Verge" /><h1 class="wp-block-heading" id="z2LKSH">Lying about Nicotine to Avoid Regulation</h1>
<p>Vaping advocates often describe e-cigarettes as revolutionary technology that competes with Big Tobacco, and was <a href="https://www.google.com/patents/US20060196518">patented </a>in 2003 <a href="https://www.google.com/patents/US20060196518">by Hon Lik</a>, a Chinese pharmacist who wanted to quit smoking. Yet, internal industry documents released through litigation show that tobacco companies created prototypes of electronic cigarettes decades before Lik introduced his product.</p>

<p>In 1962, British American Tobacco-contracted <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=nmlk0203">scientists began work on a &ldquo;smoking device</a>&rdquo; to deliver nicotine without tar, <a href="http://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2017.303806">a review of once-secret documents</a> by Stanford historian Stephan Risi shows, &ldquo;avoiding the well-known disadvantages inherent in <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=nmlk0203">actual cigarette smoking</a>.&rdquo; Top brass ultimately deemed the device a hard sell and abandoned it. Another tobacco company, Brown &amp; Williamson, had &ldquo;made solid progress&rdquo; on <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=mqvv0205">&ldquo;radical smoking products&rdquo;</a> that impart flavor &ldquo;in the absence of tobacco combustion&rdquo; by 1989, but ditched the <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=jjjv0199">project</a> to avoid infringing on a patent held by Reynolds. Philip Morris explored electronic nicotine delivery technology in 1990, <a href="http://tobaccocontrol.bmj.com/content/early/2016/11/15/tobaccocontrol-2016-053406.full#ref-5">scientists reported in the journal <em>Tobacco Control</em> last year</a>, hoping to address health concerns and the proliferation of smoke-free laws. But after the FDA announced in 1994 that it was studying nicotine&rsquo;s pharmacological effects and whether the industry intended cigarettes and smokeless tobacco to deliver these effects, executives decided the project &ldquo;complicates our efforts <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=nhfg0175">to resist the FDA&rsquo;s attempts to regulate the tobacco industry</a>,&rdquo; and dropped it.</p>

<p>The idea then, as now, was to develop a product that reduced the harm of smoking. And as part of that effort, the tobacco industry then, like the vaping industry today, denied the harmful effects not just of tar &mdash; which is not present in e-cigarettes &mdash; but also of nicotine, which is.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>In 1962, British American Tobacco-contracted scientists began work on a “smoking device” </p></blockquote></figure>
<p>In April 1994, two months after the FDA announced it would study nicotine&rsquo;s effects, the chief executives of the seven largest US tobacco companies, including Philip Morris and Reynolds, <a href="https://www.youtube.com/watch?v=e_ZDQKq2F08">lied under oath</a> before a congressional subcommittee to deny that nicotine is addictive, even as they manipulated nicotine levels to promote addiction. These deceptions came to light in July 1995, when tobacco control researcher <a href="http://jamanetwork.com/journals/jama/fullarticle/389237">Stanton Glantz and his colleagues</a> published the first in a series of papers <a href="https://jamanetwork.com/journals/jama/article-abstract/389243?resultClick=1">that analyzed thousands of formerly confidential industry documents</a>.</p>

<p>The next month, <a href="http://www.presidency.ucsb.edu/ws/?pid=51727">President Bill Clinton proposed</a> sweeping regulations to curb teen smoking, noting that the FDA&rsquo;s 14-month study confirmed that &ldquo;cigarettes and smokeless tobacco are harmful, highly addictive and aggressively marketed to our young people.&rdquo; Cigarettes and smokeless tobacco &ldquo;fall well within the definitions of drug and device,&rdquo; <a href="https://www.gpo.gov/fdsys/pkg/FR-1995-08-11/pdf/95-20052.pdf">the FDA had explained</a>, because they deliver nicotine, a drug that affects the body partly by creating and sustaining addiction as tobacco companies intended.</p>
<iframe frameborder="0" width="512" height="330" src="https://www.c-span.org/video/standalone/?c4571082"></iframe>
<p>Philip Morris, Reynolds, and a coalition of tobacco interests wasted no time filing lawsuits, using an argument that vaping interests would later tweak. Cigarettes aren&rsquo;t drugs or devices, they argued, but tobacco products, which the agency has no authority to regulate. The Competitive Enterprise Institute &mdash; which now runs interference for the vaping industry &mdash; quickly stepped in to ridicule the proposed rules. Caffeine and nicotine affect the same organs, argued Competitive Enterprise Institute general counsel Sam Kazman <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=zrlw0036">in a petition</a>, so the agency may as well regulate caffeinated beverages as drugs and devices. Kazman <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=lzyy0043">acknowledged the petition was a stunt</a>, but tobacco executives took his ploy a step further to <a href="http://tobaccocontrol.bmj.com/content/tobaccocontrol/15/suppl_4/iv27.full.pdf">argue in court that nicotine is no more harmful</a> than caffeine &mdash; a canard promoted by <a href="http://www.tobaccoharmreduction.org/wpapers/006v1.pdf">vaping advocates</a> today.</p>

<p><a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=flcj0169">Philip Morris paid the Competitive Enterprise Institute $200,000</a> that year as part of its public policy program, and would pay the think tank an additional $445,000 over the next six years. <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=zhvf0094">Reynolds</a> also funded the institute, which in turn joined Americans for Tax Reform and the Heartland Institute in a Reynolds-backed front group called &ldquo;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805008/">Get Government Off Our Back</a>&rdquo; (GGOOB) to fight indoor smoking laws and other federal tobacco regulations.</p>

<p>As <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=ffvv0089">GGOOB vowed</a> to &ldquo;protect Americans from the regulators&rsquo; heavy-handed tactics,&rdquo; tobacco companies hashed out what would be the largest civil litigation settlement in US history. Forty-six state attorneys general, five US territories, and the District of Columbia sued the companies for deceptive and fraudulent practices under consumer protection and antitrust laws to recover the substantial health care costs associated with smoking. The so-called Master Settlement Agreement dismissed existing and future suits against the companies in exchange for <a href="http://tobaccocontrol.bmj.com/content/13/4/356.long">billions</a> in annual payments to compensate the states.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Tobacco companies co-opted “harm reduction” from an Institute of Medicine report</p></blockquote></figure>
<p>But tobacco companies had already hatched plans to reinvent their image &mdash; and marginalize <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=ryyk0006">their &ldquo;enemies</a>.&rdquo; A review of Philip Morris and British American Tobacco internal documents <a href="http://tobaccocontrol.bmj.com/content/24/2/182.full">published in <em>Tobacco Control</em> shows</a> <a href="http://tobaccocontrol.bmj.com/content/24/2/182.full">that the companies</a> co-opted &ldquo;harm reduction&rdquo; from an Institute of Medicine report as a way to gain access to public health experts and <a href="https://link.springer.com/article/10.1007/s10551-012-1250-5#CR132">cast themselves as socially responsible corporations</a>. They sought <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=lghb0013">to &ldquo;challenge the credibility&rdquo; of those advocating smoking cessation and &ldquo;cause dissention&rdquo;</a> by exploiting vulnerabilities in the tobacco control movement. A Philip Morris executive argued in a&nbsp;<a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=rhcw0157">formerly confidential document</a> that recent tobacco reforms and legal victories might blind public health groups &ldquo;to carefully orchestrated efforts by the tobacco industry and its allies to accelerate turf wars and exacerbate philosophical divisions.&rdquo;</p>

<p>Toward that end, they hired PR firms to&nbsp;<a href="https://link.springer.com/article/10.1007%2Fs10551-012-1250-5">create divisions</a> among tobacco control experts and weaken public health policy by identifying moderates who might promote &ldquo;safer&rdquo; products while attacking the credibility of moralistic &ldquo;extremists&rdquo; who wouldn&rsquo;t.</p>

<p>It&rsquo;s impossible to tell whether the tobacco industry&rsquo;s efforts to cause dissension among tobacco control experts accounts for the polarized debate on vaping today. The industry <a href="https://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-4-2">has a history</a> of destroying documents that might have revealed whether they carried out their plans. What&rsquo;s clear, however, is that the industry continued to call on &ldquo;<a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=nsbk0093">credible third parties</a>&rdquo; like the Competitive Enterprise Institute and Americans for Tax Reform to fight regulations by attacking inconvenient research results and highlighting &ldquo;abuses&rdquo; of government-funded anti-tobacco programs. And now the same third parties are helping vaping interests protect e-cigarettes.</p>
<div class="wp-block-vox-media-highlight vox-media-highlight alignnone"><h1 class="wp-block-heading" id="Ranbqd">A History of Promoting Reduced Harm</h1>


<p>E-cigarettes are the latest in a series of products tobacco companies have claimed reduce the risk of smoking. Public health officials have long urged independent testing of the tobacco industry&rsquo;s reduced-harm claims &mdash; just as they are for e-cigarettes today &mdash; earning the wrath of reduced-harm activists who see their calls for evidence as condemning smokers to &ldquo;quit or die.&rdquo;</p>



<p>David Sweanor, a lawyer with a track record of successful lawsuits against the tobacco industry who considers vaping a public health breakthrough, had similar hopes for Eclipse, a &ldquo;<a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=mqpn0186">reduced risk</a>&rdquo; cigarette made by Reynolds. The tobacco giant claimed in media talking points, <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=jtwy0221">outlined in a formerly confidential document</a>, that the &ldquo;heat not burn&rdquo; technology used in Eclipse &mdash; which looks like a cigarette but doesn&rsquo;t burn down, much like an e-cigarette and <a href="https://www.pmi.com/smoke-free-products/iqos-our-tobacco-heating-system">Philip Morris&rsquo; new iQOS</a> &mdash; reduced levels of carcinogens by 80 percent. Reynolds hoped to get Sweanor&rsquo;s support for its new product, a <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=tlkx0011">1999 plan to build &ldquo;positive awareness&rdquo;</a> shows. Sweanor was anxious to promote the concept of reduced harm. &ldquo;I have already done 12 radio interviews on your Eclipse announcement so far today,&rdquo; he wrote at one point <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=fznh0221">in an email </a>to Reynolds&rsquo; head of product development. &ldquo;It is certainly getting attention. Now, hopefully, it can also be tied into both public health goals and commercial realities.&rdquo;</p>


<div class="youtube-embed"><iframe title="Eclipse Cigarette Promotional Video" src="https://www.youtube.com/embed/Yd-Pvijj5XY?rel=0" allowfullscreen allow="accelerometer *; clipboard-write *; encrypted-media *; gyroscope *; picture-in-picture *; web-share *;"></iframe></div>


<p>Brad Rodu, an oral pathologist who promotes vaping as a less harmful alternative to cigarettes, approached Reynolds with <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=qfdj0091">unsolicited advice</a> on marketing Eclipse. Reynolds should emphasize that Eclipse produces fewer toxic chemicals compared with other products because the tobacco isn&rsquo;t burned, Rodu suggested.</p>



<p>Rodu, the endowed chair in Tobacco Harm Reduction Research at the University of Louisville&rsquo;s James Graham Cancer Center &mdash; established with over $3 million in unrestricted funds from U.S. Smokeless Tobacco and Swedish Match North America, Inc. &mdash;&nbsp;now defends vaping for the R Street Institute, a libertarian think tank founded in 2012 by former Heartland Institute staffers. The Heartland Institute received $325,000 in &ldquo;public policy&rdquo; grants from Philip Morris (now known as Altria) in the 1990s; $200,000 from Reynolds and Philip Morris in 2010 and 2011, <a href="http://d35brb9zkkbdsd.cloudfront.net/wp-content/uploads/2012/02/1-15-2012-2012-Fundraising-Plan.pdf">internal documents</a> leaked to <em>ThinkProgress</em> show; and <a href="http://d35brb9zkkbdsd.cloudfront.net/wp-content/uploads/2012/02/1-15-2012-2012-Fundraising-Plan.pdf">anticipated receiving</a> another $160,000 from both companies in 2012. Altria has listed R Street as a grantee since 2014.</p>



<p>Rodu and William Godshall co-wrote a <a href="https://harmreductionjournal.biomedcentral.com/articles/10.1186/1477-7517-3-37">2006 paper</a> for the American Council on Science and Health that promoted alternative sources of nicotine to reduce the risks of smoking. In addition to offering Reynolds marketing tips on Eclipse, Rodu had defended smokeless tobacco as &ldquo;98 percent safer than smoking&rdquo; three years earlier at a <a href="https://www.gpo.gov/fdsys/pkg/CHRG-108hhrg87489/html/CHRG-108hhrg87489.htm">US House hearing</a> on tobacco harm reduction. The hearing, called &ldquo;Can Tobacco Cure Smoking? A Review of Tobacco Harm Reduction,&rdquo; had been called by Rep. Billy Tauzin (R-LA), who&rsquo;d received over $89,000 from U.S. Smokeless Tobacco, Reynolds, Philip Morris, and their employees between 1999 and 2004. Echoing Rodu was Richard Verheij, executive vice president of U.S. Smokeless Tobacco, which awarded Rodu a $1.25 million grant in 1999. After the paper came out, Rodu received additional funding from U.S. Smokeless Tobacco as well as grants from Reynolds American, Altria, Swedish Match, and British American Tobacco.</p>



<p>The American Council on Science and Health, which describes itself as a defender of &ldquo;sound science,&rdquo; received, or expected to receive, at least $419,700 from both cigarette and e-cigarette makers in 2012 and 2013, <a href="https://usrtk.org/wp-content/uploads/2017/06/acsh-financial-summary.pdf">documents leaked</a> to <em>Mother Jones</em> show, and continued to receive undisclosed sums from Altria until 2015. &nbsp;&nbsp;</p>


<figure class="wp-block-pullquote alignleft"><blockquote><p>Godshall attacks public health officials as “anti-tobacco extremists”</p></blockquote></figure>


<p>In their American Council on Science and Health paper, Godshall and Rodu argued that smokers are told to &ldquo;quit or die&rdquo; when government agencies should be telling them that smokeless tobacco is much safer than smoking. Reynolds, which <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=xhxj0222">had also been thinking</a> about how to counter the &ldquo;quit or die&rdquo; narrative, knew it lacked the credibility to &ldquo;deliver the Harm Reduction message,&rdquo; and aimed to focus on &ldquo;utilizing credible third party public health and elected officials&rdquo; and &ldquo;driving the wedge between the two opposing &lsquo;Community&rsquo; groups deeper and wider.&rdquo;</p>



<p>Reynolds appeared to consider Rodu and Godshall, who says he &ldquo;never received one dollar from any tobacco or e-cigarette company,&rdquo; as credible third parties. The company shared Godshall and Rodu&rsquo;s harm-reduction manifesto in its <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=hhbn0222">2008 Corporate Social Responsibility Report</a>. Godshall distributed it on antismoking listservs &mdash; <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=ynlm0179">blind copying Reynolds&rsquo;</a> senior director of public issues &mdash; and <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=gpjm0179">asked top Reynolds executives</a> to give reporters his number so he could correct &ldquo;biased&rdquo; journalism. Godshall says at the time he was urging Reynolds to actively promote its new snus product as less hazardous than cigarettes. He originally attributed the blind cc to &#8220;email problems,&#8221; then later said he didn&#8217;t remember the specific email, and regarded questions about his emails to tobacco executives as a smear campaign. &ldquo;I talk to anybody I feel can be helpful in reducing disease and death from cigarettes,&rdquo; he says. &ldquo;I was called a traitor for even going to talk to the industry.&rdquo; In a <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=txxd0152">letter forwarded</a> to top Reynolds marketing and communications executives, Godshall attacks public health officials as &ldquo;anti-tobacco extremists&rdquo; who &ldquo;are deceiving smokers and the public about the health risks of different tobacco products [and] nicotine.&rdquo;</p>



<p>The courts, however, ruled that it was the tobacco companies that were practicing deception. In 2010, U.S. Smokeless Tobacco&rsquo;s new owner, Altria, <a href="http://http/www.koskoff.com/Articles/Chewing-Tobacco-Co-Pays-5-Million-for-Mouth-Cancer-Victim-s-Death.shtml">paid $5 million</a> to the family of a man who started chewing tobacco when he was 13, unaware of the risks, and died following a diagnosis of tongue cancer. Carl Phillips, former scientific director and former board member for Consumer Advocates for Smoke-Free Alternatives, had testified as an expert witness on behalf of U.S. Smokeless Tobacco. Phillips, who <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=ksgl0001">received $20,000 for his work</a>, said he believed smokeless tobacco does not cause tongue or oral cancer, even though the National Toxicology Program had already concluded it does.</p>



<p>In 2013, a <a href="https://oag.ca.gov/sites/all/files/agweb/pdfs/tobacco/eclipse-final-judg-perm-injunc-opinion.pdf">Vermont Superior Court judge ordered</a> Reynolds to pay the state $8.3 million in civil penalties for <a href="https://oag.ca.gov/sites/all/files/agweb/pdfs/tobacco/eclipse-final-judg-perm-injunc-opinion.pdf">making deceptive</a> and scientifically unsupported health claims in its marketing and advertising material in violation of state consumer protection laws and the Master Settlement Agreement. And in 2015 &mdash; two decades after Reynolds marketed Eclipse as a reduced-risk cigarette &mdash; <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532619/">Mayo Clinic researchers</a> using state-of-the-art toxicity screens reported that smoke from Eclipse cigarettes was every bit as toxic as smoke from other cigarettes.</p>
</div><img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/9689385/acastro_171013_2138_0003.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="" data-portal-copyright="Illustrations by Alex Castro / The Verge" /><h1 class="wp-block-heading" id="GnamJB">Tobacco-funded Libertarians Lend a Hand</h1>
<p>As of September 2017, eight states and the District of Columbia have passed laws to tax e-cigarettes. Every state except Michigan has at least one law on the books specifically regulating e-cigarettes, and in many states, including Michigan, local governments have adopted stronger rules. Where public health experts see taxes and regulations as proven strategies to reduce the use of tobacco and its alternatives, vaping advocates view the measures as an assault on their livelihood and individual rights. Their campaigns to fight taxes and regulations have been taken up by far-right libertarian activists like Grover Norquist, founder of Americans for Tax Reform, which has received over $1 million from Philip Morris and Reynolds since the mid-1990s. Norquist praised vapers on his podcast for helping to defeat the 2014 reelection bid of a New Mexico state representative who proposed taxing e-cigarettes as tobacco products, and for beating back tax increases in 26 states.</p>

<p>Last year, Americans for Tax Reform&rsquo;s Paul Blair joined the Consumer Advocates for Smoke-Free Alternatives Association and the American Vaping Association on a multi-state &ldquo;Right to Vape&rdquo; tour to &ldquo;raise awareness&rdquo; that the FDA&rsquo;s proposed regulations on e-cigarettes would destroy the industry. At a stop in Wisconsin, the rally&rsquo;s emcee introduced an &ldquo;activist and warrior for the cause,&rdquo; Aaron Biebert, director of the cinematic valentine to vaping <em>A Billion Lives</em>. In the movie, named for cigarettes&rsquo; projected death toll over the next century, Biebert lays out a conspiracy to discredit vaping among puritanical &ldquo;prohibitionists&rdquo; who insist smokers &ldquo;quit or die,&rdquo; corrupt federal health officials addicted to revenues from tobacco industry taxes and lawsuits, and drug companies intent on quashing their competition.</p>
<div class="youtube-embed"><iframe title="A Billion Lives - Official Trailer" src="https://www.youtube.com/embed/nCozEhqdKQw?rel=0" allowfullscreen allow="accelerometer *; clipboard-write *; encrypted-media *; gyroscope *; picture-in-picture *; web-share *;"></iframe></div>
<p>Glosses on this theory echo across blogs, social media, vaping forums, and right-wing media channels. Biebert&rsquo;s vilification of the federal government earned him spots on the Herman Cain Show, hosted by the 2012 Republican presidential candidate and Tea Party favorite, and the <a href="https://www.mixcloud.com/heartlanddailypodcast/aaron-biebert-e-cigarettes-and-a-billion-lives/">podcast of the Heartland Institute</a>, the free-market think tank that took money from Exxon while attacking the science of climate change. Perhaps less well-known is that the Heartland Institute, which took at least $325,000 from Philip Morris in the 1990s, also helped the tobacco industry deny the evidence that <a href="https://www.heartland.org/publications-resources/publications/july-1998-five-lies-about-tobacco-the-tobacco-bill-wasnt-about-kids">secondhand smoke harms</a> bystanders &mdash; and <a href="https://www.heartland.org/_template-assets/documents/publications/1532.pdf">that Philip Morris</a> targeted kids with its Joe Camel cartoons.</p>

<p>On <a href="https://www.youtube.com/watch?v=q6XmoJyue3Q">Cain&rsquo;s show</a>, Biebert explained his movie&rsquo;s central premise: e-cigarettes would save a billion lives if not for corrupt public health officials who lie about the risks of nicotine and vaping to promote innovation-destroying regulations that will kill an industry. &ldquo;You can tell it&rsquo;s kind of crooked, because it just doesn&rsquo;t make sense,&rdquo; Biebert said. &ldquo;There&rsquo;s no science to back it up and here they are shutting down 20,000 businesses, and they don&rsquo;t care.&rdquo; (Vapers&rsquo; estimates of vape shops tend to run higher than public health officials&rsquo;.) Biebert went on to say that, time and again, studies show that the air around vapers is no different from &ldquo;regular air.&rdquo; Cain, who fought indoor smoking restrictions and <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=lmcf0094">took money from Reynolds</a> as head of the National Restaurant Association, wrapped up the interview saying, &ldquo;Big Brother has lied again to the American people.&rdquo;</p>

<p><em>A Billion Lives</em> calls on veteran anti-smoking activists to attack the &ldquo;anti-tobacco industry&rdquo; for not promoting vaping as a public health &ldquo;miracle.&rdquo; By presenting an alternative to cigarettes, contends David Sweanor, adjunct professor at the Centre for Health Law, Policy and Ethics at the University of Ottawa, vaping offers the &ldquo;opportunity to do something that would rival the eradication of smallpox.&rdquo; Godshall, an ardent defender of vaping, describes his idea of the perfect solution to the cigarette epidemic: it would be 99 percent less hazardous than cigarettes, wouldn&rsquo;t be addicting nonsmokers, wouldn&rsquo;t encourage anyone to switch to cigarettes, and would help lots of people quit smoking. &ldquo;And it&rsquo;s called vaping.&rdquo; &nbsp;</p>

<p>Both Sweanor and Godshall, who broke with mainstream tobacco control experts over a decade ago, have long promoted alternative tobacco products to reduce the harm associated with smoking (see &ldquo;A History of Promoting Reduced Harm,&rdquo; above).</p>

<p>Sweanor told me he believes vaping could force the tobacco industry to stop selling cigarettes. &ldquo;If the vast majority of the risk is from the smoke, and you can deliver what consumers would like without the smoke in a far less addictive way so you can greatly reduce their health risk and you can facilitate them getting off the product entirely if that&#8217;s what they want to do,&rdquo; he asks, &ldquo;then how do you justify selling cigarettes?&rdquo;</p>

<p>Sweanor believes officials should inform smokers that different tobacco products carry different risks, rather than telling them to quit tobacco. &ldquo;We&#8217;ve got 6 million plus deaths per year, virtually all because of a dirty delivery system,&rdquo; he told me.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“Maybe e-cigarettes are 50 percent safer, or 25 percent safer, or maybe they are just as bad as cigarettes in ways that we do not know.”</p></blockquote></figure>
<p>But are e-cigarettes a clean nicotine delivery system? That&rsquo;s not what the scientific evidence shows, Soneji says. &ldquo;Maybe e-cigarettes are 50 percent safer, or 25 percent safer, or maybe they are just as bad as cigarettes in ways that we do not know.&rdquo;</p>

<p>The concerted efforts to discount evidence from studies finding cause for concern about vaping echo the tactics of tobacco industry-funded scientists who questioned the link between cancer and smoking, Soneji notes. They sowed confusion and skepticism to undermine a growing body of evidence of smoking&rsquo;s harms, which helped delay regulations on cigarettes for decades. The research on e-cigarettes is just beginning, he says, yet advocates are simply dismissing potential harms while cheerleading the benefits of vaping far beyond what the science supports.</p>

<p>Godshall, in contrast, insists the science is settled. He blames the &ldquo;left-wing&rdquo; media and government-funded scientists for spreading misinformation about the benefits of vaping. &ldquo;The headlines and the news are confusing and deceiving the public about the science,&rdquo; he says. &ldquo;Many of the people who are being paid to conduct the science have been knowingly and intentionally manipulating their results, omitting results, selectively cherry picking and basically misrepresenting their own findings because they&rsquo;re getting federal funding.&rdquo;</p>

<p>Where did Godshall get the evidence that vaping is 99 percent safer than smoking? &ldquo;Basically every study that&rsquo;s ever been published,&rdquo; he told me.</p>
<h1 class="wp-block-heading" id="i937Yu">Recycling Old Claims</h1>
<p>Long before scientists began studying vaping&rsquo;s potential harms and benefits, distributors marketed e-cigarettes as a &ldquo;healthier way to smoke.&rdquo; Ads featuring scantily clad women claimed e-cigarettes could help smokers &ldquo;<a href="http://www.keepsmokinganywhere.com/">stop the habit</a>&rdquo; and get &ldquo;<a href="http://www.safesmoke.us/oldfiles_alps/index.html">real nicotine</a> in a harmless water vapor that you can smoke&#8230;virtually anywhere!&rdquo; Where smokers saw a new gadget to satisfy their nicotine cravings, the FDA saw companies peddling a drug with unsubstantiated health claims. And in the spring of 2009, the agency blocked imports of e-cigarettes <a href="https://www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM173191.pdf">made by three Chinese manufacturers</a> as unapproved drug delivery devices. &nbsp;</p>

<p>Smoking Everywhere, which imported and distributed the Chinese products, promptly <a href="http://www.fdalawblog.net/files/smoking-everywhere---complaint.pdf">sued the FDA</a>, tweaking the argument tobacco companies had made a decade earlier: e-cigarettes are not nicotine or drug delivery devices, but tobacco products and therefore outside the agency&rsquo;s jurisdiction. E-cigarette distributor NJOY soon joined the lawsuit, and CASAA, Godshall, and several other vaping advocates later <a href="http://casaa.org/wp-content/uploads/amicus_brief_smokefree-7-8-2010.pdf">filed a supporting brief</a>.</p>

<p>Several months after seizing the products, the FDA <a href="https://web.archive.org/web/20161210112502/http://www.fda.gov:80/newsevents/newsroom/pressannouncements/ucm173222.htm">announced</a> that its scientists had detected tobacco-related carcinogens and toxic chemicals in some of the samples. The industry&rsquo;s libertarian allies quickly rose to its defense. The American Council on Science and Health condemned the FDA for needlessly scaring the public, while Brad Rodu and Joel Nitzkin of the R Street Institute <a href="http://www.standardnewswire.com/news/162574365.html">cast doubt</a> on the agency&rsquo;s science. Godshall for his part <a href="http://www.smokeversusvapor.com/fdareportsummary.htm">urged the FDA</a> to consider a test by e-cigarette manufacturer Ruyan, which he said found &ldquo;no product hazards.&rdquo;</p>

<p>Godshall also actively partnered with vaping companies. &ldquo;I was the person who got the two owners of NJOY and Smoking Everywhere together and helped coordinate their legal team,&rdquo; he told me. NJOY and Smoking Everywhere hired the same firms that helped the tobacco industry <a href="https://webcache.googleusercontent.com/search?q=cache:WnEj08tXa00J:https://www.law360.com/articles/316321/us-to-appeal-ruling-nixing-fda-s-cigarette-warning-labels+&amp;cd=3&amp;hl=en&amp;ct=clnk&amp;gl=us">evade regulation</a> and <a href="https://law.justia.com/cases/federal/district-courts/FSupp/865/665/1505802/">defeat smokers&rsquo; liability claims</a> for years. And their allies, including CASAA and Godshall, hired <a href="http://law.justia.com/cases/federal/district-courts/FSupp/865/665/1505802/">law firms that had successfully defended</a> tobacco companies Brown &amp; Williamson and Philip Morris against class action lawsuits brought by smokers seeking compensation from an industry they said lied about its products&rsquo; lethal nature.</p>

<p>Bringing in veteran tobacco industry lawyers paid off. Nine months after Smoking Everywhere filed suit, a <a href="https://www.gpo.gov/fdsys/pkg/USCOURTS-dcd-1_09-cv-00771/pdf/USCOURTS-dcd-1_09-cv-00771-1.pdf">federal judge ordered the FDA</a> to stop seizing e-cigarette shipments.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“There is no smoke associated with e-cigarettes. So to call them smoking devices is ridiculous.”</p></blockquote></figure>
<p>In the absence of federal oversight, state and city officials proposed their own measures to regulate vaping. In spring 2014, the Philadelphia City Council proposed adding e-cigarettes to indoor smoking laws and prohibiting their sale to minors. CASAA quickly issued a <a href="http://blog.casaa.org/2014/02/call-to-action-philadelphia-e-cigarette.html">call to action</a> and distributed talking points to help vapers oppose the measures. CASAA describes itself as a grassroots organization devoted to ensuring the availability of <a href="http://casaa.org/gallery-with-sidebar/">reduced harm alternatives to smoking</a>. Yet <a href="https://sharepoint.louisville.edu/sites/bcc/faculty/Faculty%20CV/Rodu%20CV.pdf">former</a> <a href="http://tobaccoharmreduction.org/thr2010alo.pdf">board</a> members have received research grants from Philip Morris, R.J. Reynolds, British American Tobacco, US Smokeless Tobacco Company, and Swedish Match, which also makes smokeless tobacco.</p>

<p>Godshall, Gilbert Ross, then-executive director of the American Council on Science and Health, and R Street Institute&rsquo;s Nitzkin also showed up to defend vaping. Defining e-cigarettes as smoking devices is &ldquo;a major distortion of the truth,&rdquo; <a href="http://legislation.phila.gov/transcripts/Public%20Hearings/health/2014/ph031314.pdf">Nitzkin told the city council</a>. Godshall urged the council to reject the bills, saying the vaping ban &ldquo;deceitfully defines smoke-free e-cigarettes as electronic smoking.&rdquo; Ross offered his own variation on the vaping isn&rsquo;t smoking trope. &ldquo;There is no smoke associated with e-cigarettes,&rdquo; Ross said. &ldquo;So to call them smoking devices is ridiculous.&rdquo;</p>

<p>Yet that&rsquo;s exactly what the vaping companies and their supporters called e-cigarettes in their FDA lawsuit. Smoking Everywhere &mdash; as its name suggests &mdash; <a href="http://casaa.org/wp-content/uploads/SE-v-FDA-original-complaint-4-28-09.pdf">described itself as a</a> &ldquo;corporation that has pioneered the marketing and importation of electronic smoking devices&#8230;marketed, labeled, and sold solely to provide adult consumers with alternative &lsquo;smoking&rsquo; pleasure, without the inconveniences of traditional tobacco smoking.&rdquo;</p>

<p>Godshall also resurrected the argument Kazman of the Competitive Enterprise Institute used to ridicule the FDA&rsquo;s first attempt to regulate nicotine as a drug. &ldquo;So, I mean, why don&rsquo;t you ban coffee?&rdquo; Godshall asked. &ldquo;It&rsquo;s got carcinogens in it, toxic chemicals.&rdquo;</p>

<p>The Philadelphia City Council, supported by the local health department, didn&rsquo;t buy his argument. Both bills passed in a unanimous votes in March 2014, a month before the FDA finally proposed its &ldquo;deeming&rdquo; rule to regulate e-cigarettes as tobacco products.</p>

<p>States have had less success than cities in passing e-cigarette legislation. In California, then-state Senator Ellen Corbett introduced a bill in 2013 to prohibit the sale of e-cigarettes in vending machines and regulate them like any other tobacco product. CASAA <a href="http://blog.casaa.org/2013/03/call-to-action-california-e-cigarette.html">again rallied its base</a> to fight the measure, arguing that e-cigarettes aren&rsquo;t tobacco products, exactly the opposite of what the group claimed in a brief supporting Smoking Everywhere&rsquo;s lawsuit.</p>

<p>In the past, cigarette companies had to create phony grassroots smokers&rsquo; rights groups to take their case to the public, says UCSF&rsquo;s Stanton Glantz. &ldquo;Now there are grassroots groups that popped up on their own that tobacco companies hide behind.&rdquo;</p>

<p>And as vaping advocates fight regulations in public hearings, tobacco companies work the halls and back rooms of the capitol. Philip Morris, Reynolds American, and its allies paid lobbyists nearly $1.2 million over the 2013&ndash;14 election cycle to fight Corbett&rsquo;s bill and other tobacco legislation, a review of campaign filings shows, while NJOY kicked in an additional $88,105. When the bill emerged from the Assembly Governmental Organization Committee &mdash; which tobacco control advocates call the &ldquo;place where tobacco control bills go to die&rdquo; &mdash; e-cigarettes were no longer defined as tobacco products. The bill died after many health advocates reluctantly withdrew their support.</p>

<p>Former California state Senator Mark Leno also tried to regulate e-cigarettes as tobacco products in 2015. This time, the Northern California chapter of the Smoke-Free Alternatives Trade Association (SFATA) mobilized vapers. In opposing the bill, former Norcal SFATA director Stefan Didak told legislators he&rsquo;s never taken money from the vaping or tobacco industry. He didn&rsquo;t mention that SFATA&rsquo;s board members included a former senior marketing executive for Philip Morris and a National Tobacco Company executive who claimed to have <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265275/">shredded a million incriminating</a> documents for the tobacco industry in the 1990s and founded a company that makes synthetic nicotine.</p>

<p>Altria and its allies paid their lobbyists over $908,700 to fight Leno&rsquo;s measure, while NJOY and SFATA spent $67,500. And again, the Governmental Organization Committee changed the bill&rsquo;s language to say that e-cigarettes are not tobacco products. &ldquo;The chair of the Assembly committee attempted to completely hijack our bill by creating a new definition of e-cigarettes, which was exactly what the tobacco industry wanted,&rdquo; Leno told me. &ldquo;We had to walk away from our own bill.&rdquo;</p>

<p>The tobacco and vaping industries have spent nearly $10 million to fight regulations on e-cigarettes and related legislation in California since 2009, state records show. Altria and Reynolds American spent over $70 million in 2016 alone to fight taxes on tobacco and e-cigarettes in California. It took a special session called by Governor Jerry Brown to get around the Assembly Governmental Organization Committee. Leno reintroduced his original bill, which passed last year along with what health advocates call the most wide-reaching package of tobacco control legislation in decades.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Recent research shows that e-cigarette users have more carcinogens in their urine than nonusers</p></blockquote></figure>
<p>The scope of tobacco industry spending to influence policy is no surprise to Samir Soneji, who&rsquo;s well-versed in the industry&rsquo;s tactics. He remains troubled that tobacco-control allies who once exposed the tobacco industry&rsquo;s deceptions seem to accept the same actions by the e-cigarette industry. &ldquo;It might be the same playbook but they don&rsquo;t make that connection.&rdquo;</p>

<p>Even so, the summit made him think differently about the concerns of people whose lives and livelihoods are tied to vaping. It helped him understand why adult smokers who can&rsquo;t quit despite repeated attempts are willing to try e-cigarettes before there&rsquo;s conclusive evidence that they work. He&rsquo;s even thinking of returning to the meeting next year so he can &#8220;rile up some more animosity,&rdquo; he says, recalling the boos his last appearance provoked. He&rsquo;s curious if anyone will change their view of vaping in light of new studies, which are &ldquo;coming out constantly.&#8221; Recent research shows that e-cigarette users have more carcinogens in their urine than nonusers, for example, in contrast to studies presented at the summit that &ldquo;heavily discounted&rdquo; their toxicity.</p>

<p>Vaping interests, meanwhile, continue to discount e-cigarettes&rsquo; harms as they&rsquo;ve redoubled efforts to fight restrictions on the devices. After the FDA finalized its rule to regulate e-cigarettes as tobacco products last year, vaping companies and their allies again tapped tobacco industry lawyers to fight the FDA. Nicopure, which makes e-liquids and e-cigarettes, hired the <a href="https://www.industrydocumentslibrary.ucsf.edu/tobacco/docs/#id=knyw0128">same law firm</a> that ran Philip Morris&rsquo; Whitecoat operation to cast doubt on the dangers of secondhand smoke. The suit again challenged the agency&rsquo;s jurisdiction and argued that the rule violated companies&rsquo; constitutional rights to free speech by preventing e-cigarette manufacturers from making truthful statements about its products. &ldquo;Notwithstanding plaintiffs&rsquo; rhetoric,&rdquo; a federal judge wrote in rejecting the claims in July, &ldquo;this provision does not ban truthful statements about health benefits or reduced risks; it simply requires that they be substantiated.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p> “Banning e-cigarettes would actually increase transportation-related deaths by driving nicotine-dependent passengers to drive rather than fly,” their opening brief argued</p></blockquote></figure>
<p>The industry tried a more creative approach last year, when <a href="https://cei.org/litigation/cei-v-dot">CASAA and the Competitive Enterprise Institute</a> sued the Department of Transportation to overturn a rule extending the smoking ban on airplanes to e-cigarettes. &ldquo;Banning e-cigarettes would actually increase transportation-related deaths by driving nicotine-dependent passengers to drive rather than fly,&rdquo; their opening brief argued, &ldquo;and would undermine rather than promote passenger comfort by subjecting passengers to nicotine withdrawal symptoms that are a common cause of &ldquo;air rage.&rdquo; A federal appeals court rejected their argument in July.</p>

<p>Tobacco control advocates scored another win during the summer, when San Francisco passed an ordinance banning the sale of flavored tobacco products. Within weeks, a group called Let&rsquo;s Be Real, heavily promoted by by SFATA&rsquo;s Didak, launched a voter petition to repeal the ban. The <a href="https://cei.org/content/fears-aren%E2%80%99t-facts-e-cigarettes">Competitive Enterprise Institute</a>, <a href="http://www.rstreet.org/op-ed/vape-flavor-ban-threatens-san-franciscos-legacy-of-harm-reduction/">R Street</a>, and other tobacco industry allies also attacked the ban, which suggests that they fear other cities will follow suit. Let&rsquo;s Be Real announced in August that it had collected far more than the required number of <a href="https://www.vapingpost.com/2017/08/03/petition-against-flavor-ban-submitted-to-authorities-in-sf/">signatures</a> to force a referendum on the flavor ban.</p>

<p>Where things get real is on the bottom line. San Francisco&rsquo;s strict campaign disclosure laws require petitioners to reveal their benefactors. And the first part of that disclosure offers voters plucky, grassroots appeal:&nbsp;&ldquo;Paid for by Let&rsquo;s Be Real San Francisco, A Coalition of Concerned Citizens Supporting Freedom of Choice, Adult Consumers, Community Leaders, and Neighborhood Small Businesses.&rdquo;</p>

<p class="has-end-mark">If that seems rosy, the punchline is somewhat more worrying: &ldquo;with Major Funding by R.J. Reynolds Tobacco Company.&rdquo;</p>

<p><em><strong>Correction:&nbsp;</strong></em>Stefan Didak was incorrectly identified as the current Norcal director of SFATA. He has left SFATA and now&nbsp;helps lead NOTBlowingSmoke. In addition, the group Let&rsquo;s Be Real was not headed by Didak, but heavily promoted by him.</p>
						]]>
									</content>
			
					</entry>
			<entry>
			
			<author>
				<name>Liza Gross</name>
			</author>
			
			<title type="html"><![CDATA[Troubling chemicals found in wide range of fast-food wrappers]]></title>
			<link rel="alternate" type="text/html" href="https://www.theverge.com/2017/2/1/14464370/fast-food-chemical-wrapper-pfas-pfoa" />
			<id>https://www.theverge.com/2017/2/1/14464370/fast-food-chemical-wrapper-pfas-pfoa</id>
			<updated>2017-02-01T08:00:02-05:00</updated>
			<published>2017-02-01T08:00:02-05:00</published>
			<category scheme="https://www.theverge.com" term="Health" /><category scheme="https://www.theverge.com" term="Science" />
							<summary type="html"><![CDATA[Americans love fast food, but the materials used to serve short-order fare may contain harmful synthetic chemicals, a new study has found. Previous research has shown these chemicals can leach into food. Paper products used to serve fried chicken, French fries, burritos, donuts, and other fast food contain chemicals that resist heat and grease and [&#8230;]]]></summary>
			
							<content type="html">
											<![CDATA[

						
<figure>

<img alt="" data-caption="Burger and curly fries | &lt;a href=&quot;https://www.flickr.com/photos/mrbling/42711932/in/photolist-4LULC-pbaqmL-6mCkEk-fe5am5-eQnMvd-coC8Jo-6KPRTG-8sXShw-obBq7e-o1Cmp2-qrkFtP-2AjLLu-GFofcq-5ciN5b-9Tbo-ndE6h-axF8dU-bk44T8-qvLWTP-7Y2cS9-bnm24G-bt96QJ-nZXKzN-icoj69-8CiMru-roe1ts-bnm1YJ-nGGJ11-bKcVPP-8PwGXQ-6vRn71-av3PS-DcnY6J-dFjYe2-83p6Cr-iJbxEG-emxeN-hU2E7V-pD2Eaq-9t8w6A-9JcWUx-4Rj4et-b3vqyM-2ZqY9-nwCn1e-qtuG6s-7Y2c3j-fmzk2e-cGwaPU-kHquJn&quot;&gt;ebruli/flickr&lt;/a&gt;" data-portal-copyright="&lt;a href=&quot;https://www.flickr.com/photos/mrbling/42711932/in/photolist-4LULC-pbaqmL-6mCkEk-fe5am5-eQnMvd-coC8Jo-6KPRTG-8sXShw-obBq7e-o1Cmp2-qrkFtP-2AjLLu-GFofcq-5ciN5b-9Tbo-ndE6h-axF8dU-bk44T8-qvLWTP-7Y2cS9-bnm24G-bt96QJ-nZXKzN-icoj69-8CiMru-roe1ts-bnm1YJ-nGGJ11-bKcVPP-8PwGXQ-6vRn71-av3PS-DcnY6J-dFjYe2-83p6Cr-iJbxEG-emxeN-hU2E7V-pD2Eaq-9t8w6A-9JcWUx-4Rj4et-b3vqyM-2ZqY9-nwCn1e-qtuG6s-7Y2c3j-fmzk2e-cGwaPU-kHquJn&quot;&gt;ebruli/flickr&lt;/a&gt;" data-has-syndication-rights="1" src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/7908269/42711932_63275a104a_o.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" />
	<figcaption>
	Burger and curly fries | <a href="https://www.flickr.com/photos/mrbling/42711932/in/photolist-4LULC-pbaqmL-6mCkEk-fe5am5-eQnMvd-coC8Jo-6KPRTG-8sXShw-obBq7e-o1Cmp2-qrkFtP-2AjLLu-GFofcq-5ciN5b-9Tbo-ndE6h-axF8dU-bk44T8-qvLWTP-7Y2cS9-bnm24G-bt96QJ-nZXKzN-icoj69-8CiMru-roe1ts-bnm1YJ-nGGJ11-bKcVPP-8PwGXQ-6vRn71-av3PS-DcnY6J-dFjYe2-83p6Cr-iJbxEG-emxeN-hU2E7V-pD2Eaq-9t8w6A-9JcWUx-4Rj4et-b3vqyM-2ZqY9-nwCn1e-qtuG6s-7Y2c3j-fmzk2e-cGwaPU-kHquJn">ebruli/flickr</a>	</figcaption>
</figure>
<p>Americans love fast food, but the materials used to serve short-order fare may contain harmful synthetic chemicals, a <a href="http://dx.doi.org/10.1021/acs.estlett.6b00435">new study</a> has found. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16227186">Previous research</a> has shown these chemicals can leach into food.</p>

<p>Paper products used to serve fried chicken, French fries, burritos, donuts, and other fast food contain chemicals that resist heat and grease and have been linked to diverse health risks, according to a study published in <em>Environmental Science &amp; Technology Letters</em>. The study did not determine whether the chemicals leached into food samples, but other <a href="https://www.ncbi.nlm.nih.gov/pubmed/17032055">studies have shown</a> the chemicals are especially likely to get into food if it&rsquo;s hot and greasy.</p>

<p>These synthetic chemicals resist oil, water, heat, and stains, thanks to super-strong fluorine-carbon bonds. That&rsquo;s made them valuable ingredients in a diverse array of products, including outdoor gear, carpets, furniture, firefighting foams, cosmetics, dental floss, microwave popcorn bags, and non-stick cookware. And the hardy bonds don&rsquo;t break down easily in the environment, either. Scientists have found these chemicals, called per- and polyfluoroalkyl substances (PFASs), most everywhere they&rsquo;ve looked, including in the tissue of <a href="http://pubs.acs.org/doi/full/10.1021/es9003894">animals like polar bears</a> that are far removed from places the chemicals are produced or used. National studies have detected them in <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072821/">nearly every American</a> tested.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Scientists have found these chemicals most everywhere they’ve looked, including in polar bear tissue<br></p></blockquote></figure>
<p>The most compelling evidence that these chemicals pose risks to human health comes from studies of people who drank water contaminated with them, says Laurel Schaider, a research scientist and environmental chemist at the Silent Spring Institute, who led the study of fast food. For decades, some 75,000 people living near DuPont&rsquo;s Washington Works plant in West Virginia were exposed to perfluorooctanoic acid (PFOA, or C8), the chemical used to make Teflon, in their drinking water. As part of a class-action settlement, an<a href="http://www.c8sciencepanel.org/newsletter10.html"> independent scientific review panel</a> concluded that six conditions were probably linked to PFOA exposure: high cholesterol, kidney cancer, testicular cancer, thyroid disease, pregnancy-induced hypertension, and ulcerative colitis, a bowel disease.</p>

<p>But drinking water is just one way people can be exposed, so Schaider decided to cast a wider net. She and a team of scientists collected over 400 samples of food- and beverage-serving materials from 27 fast-food chains around the country. With the help of a University of Notre Dame physics professor named Graham Peaslee, they were able to quickly detect total fluorine levels in their samples with a fluorine-detection method normally used by geologists.</p>

<p>Overall, a third of fast-food packaging samples contained fluorinated chemicals. Paper cups and materials that didn&rsquo;t come into direct contact with food had no chemicals. Almost half of all the paper food wrappers tested did, including 57 percent of Tex-Mex packaging, 56 percent of dessert and bread pouches, 38 percent of sandwich and burger bags, and one in five boxes for French fries and other especially greasy foods.</p>
<img src="https://platform.theverge.com/wp-content/uploads/sites/2/chorus/uploads/chorus_asset/file/7908293/5319723758_d54a8a48ec_o.jpg?quality=90&#038;strip=all&#038;crop=0,0,100,100" alt="" title="" data-has-syndication-rights="1" data-caption="Chorizo cheese fries&lt;br&gt; | &lt;a href=&quot;https://www.flickr.com/photos/theimpulsivebuy/5319723758/in/photolist-975Yx9-pZL3XJ-qJFZHN-j16JeP-9qzDme-hXV4nJ-iFBwXC-74Etji-3b3DA8-2eLNXR-9k8UfZ-7WU2oT-e8KNQy-cVh2BJ-975YLW-73U33A-e1H4yo-78SoRB-7QhWRr-B6Gsn-7JSvt2-invrW4-j366bw-7k9dgJ-rFFHh2-e1H4Dy-rFzPXf-hZ7qHj-igQbw2-j5MMLL-876hPv-rkiYMV-77NUSP-jKgd2h-4t8n4R-8aapmP-iCnZYs-hYcuBE-5CWXeG-8aakQr-rp8kTA-qJUfcT-6mNsu8-2ifSAb-rDpbwQ-7qpdNT-4tcq9N-8RuLHo-6fJJ5y-jBQSYN&quot;&gt;theimpulsivebuy/Flickr&lt;/a&gt;" data-portal-copyright="&lt;a href=&quot;https://www.flickr.com/photos/theimpulsivebuy/5319723758/in/photolist-975Yx9-pZL3XJ-qJFZHN-j16JeP-9qzDme-hXV4nJ-iFBwXC-74Etji-3b3DA8-2eLNXR-9k8UfZ-7WU2oT-e8KNQy-cVh2BJ-975YLW-73U33A-e1H4yo-78SoRB-7QhWRr-B6Gsn-7JSvt2-invrW4-j366bw-7k9dgJ-rFFHh2-e1H4Dy-rFzPXf-hZ7qHj-igQbw2-j5MMLL-876hPv-rkiYMV-77NUSP-jKgd2h-4t8n4R-8aapmP-iCnZYs-hYcuBE-5CWXeG-8aakQr-rp8kTA-qJUfcT-6mNsu8-2ifSAb-rDpbwQ-7qpdNT-4tcq9N-8RuLHo-6fJJ5y-jBQSYN&quot;&gt;theimpulsivebuy/Flickr&lt;/a&gt;" />
<p>Eight in 10 Americans say they eat at fast-food restaurants at least monthly, according to <a href="http://www.gallup.com/poll/163868/fast-food-major-part-diet.aspx">a 2013 Gallup Poll</a>, and nearly half report eating fast food at least once a week. Kids&rsquo; exposure to PFASs from fast-food packaging is especially worrisome since their bodies are still developing, making them more susceptible to toxic chemicals. That&rsquo;s not all: these chemicals can also <a href="http://jamanetwork.com/journals/jama/fullarticle/1104903">interfere with vaccinations</a>, by preventing children from mounting the normal immune response to the shot, says Philippe Grandjean, a professor of environmental health at Harvard&rsquo;s T.H. Chan School of Public Health and the University of Southern Denmark, who was not involved in the study.</p>

<p>The screening method picks up high levels of the chemicals, so the results likely underestimate their presence in food packaging, says Grandjean. &#8232;&#8232;When the team used methods that identified specific compounds, Schaider was surprised to find that some contained PFOA, a type of fluorinated chemical that U.S. manufacturers had agreed to phase out of food packaging by 2011 and altogether in 2015. The containers may have come from old inventory or from China, <a href="http://pubs.acs.org/doi/abs/10.1021/acs.est.6b03752">where production has continued</a> unabated.</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>Fast food isn’t the only source for these chemicals<br></p></blockquote></figure>
<p>The 27 fast-food chains sampled in the study include popular chains like Taco Bell, Dunkin&rsquo; Donuts, Starbucks, and McDonalds, but the study wasn&rsquo;t designed to compare chains, Schaider says. Even samples taken from a handful of independent fast-food restaurants had the chemicals.</p>

<p>Fast food isn&rsquo;t the only source for these chemicals. In a previous study, Notre Dame&rsquo;s Peaslee analyzed microwave popcorn bags sold in Washington state and found PFASs in all 15 brands tested. Since PFASs are likely to linger in butter and steam, consumers should cook popcorn the old-fashioned way: on the stove or in a hot-air popper, Peaslee says.</p>

<p>The <a href="http://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm479465.htm">U.S. Food and Drug Administration</a> no longer allows PFOA and PFOS or anything that breaks down to these so-called &ldquo;long-chain chemicals&rdquo; (named after their 8-carbon chain backbone) in food packaging. But the agency still allows over 90 fluorinated chemicals in food-contact paper. And manufacturers are switching to &ldquo;short-chain&rdquo; varieties that researchers haven&rsquo;t had a chance to study yet, Schaider says.</p>

<p>&ldquo;In some cases we don&#8217;t know exactly what the new chemicals are, but we do know the replacements are still really persistent,&rdquo; she says. &ldquo;And some of the preliminary evidence suggests they might have the same biological activity.&rdquo;</p>

<p>That&rsquo;s why Arlene Blum, who directs the Green Science Policy Institute and contributed to the study, advocates replacing the whole class of highly fluorinated chemicals. None of these chemicals break down, and even though the short-chain varieties don&rsquo;t stay as long in the body, they&rsquo;re harder to remove from drinking water, she says.</p>

<p>&ldquo;The question is, do you really need it, given the potential for harm?&rdquo; Blum says. &ldquo;Maybe you&rsquo;d rather have greasy fingers than eat fluorinated chemicals with your French fries.&rdquo;</p>
<figure class="wp-block-pullquote alignleft"><blockquote><p>“This is a solvable problem.”</p></blockquote></figure>
<p>The Danish Ministry of Foods forged an agreement with food-packaging manufacturers to produce fluorine-free materials, says environmental health expert Grandjean. &ldquo;I would recommend that the FDA initiate a similar initiative so exposures to these toxic substances can be minimized.&rdquo;</p>

<p>Blum prefers not to wait for regulators. Last year Coop Denmark, the country&rsquo;s largest retailer, announced it would no longer sell microwave popcorn. &ldquo;Six months later a Czechoslovakian company came up with an alternative,&rdquo; she says. &ldquo;This is a solvable problem.&rdquo;</p>
						]]>
									</content>
			
					</entry>
	</feed>
